Hologic (HOLX) 10-Q 28 Apr 21 2021 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Mar. 27, 2021	Apr. 22, 2021
Cover [Abstract]
Title of 12(b) Security	Common Stock, $0.01 par value
Document Transition Report	false
Document Quarterly Report	true
Entity Incorporation, State or Country Code	DE
Entity Address, Postal Zip Code	01752
Entity File Number	1-36214
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 27, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Registrant Name	HOLOGIC, INC
Entity Central Index Key	0000859737
Current Fiscal Year End Date	--09-28
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding		256,233,027
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
City Area Code	(508)
Local Phone Number	263-2900
Entity Tax Identification Number	04-2902449
Entity Address, Address Line One	250 Campus Drive,
Entity Address, City or Town	Marlborough,
Entity Address, State or Province	MA
Trading Symbol	HOLX
Security Exchange Name	NASDAQ

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Thousands	3 Months Ended		6 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Revenues:
Product	$ 1,378,800,000	$ 623,600,000	$ 2,834,200,000	$ 1,322,900,000
Service and other	158,800,000	132,500,000	313,200,000	283,700,000
Revenues	1,537,600,000	756,100,000	3,147,400,000	1,606,600,000
Costs of revenues:
Product	300,700,000	223,300,000	585,200,000	460,800,000
Amortization, Cost of Goods Sold	64,500,000	62,900,000	126,100,000	126,500,000
Impairment of intangible assets and equipment	0	0	0	25,800,000
Service and other	86,600,000	74,100,000	170,000,000	163,900,000
Gross profit	1,085,800,000	395,800,000	2,266,100,000	829,600,000
Operating expenses:
Research and development	71,500,000	49,300,000	130,700,000	110,400,000
Selling and marketing	131,500,000	110,600,000	259,500,000	255,400,000
General and administrative	88,900,000	67,000,000	180,400,000	154,700,000
Amortization of acquired intangible assets	10,200,000	10,100,000	20,400,000	19,200,000
Impairment of intangible assets and equipment	0	0	0	4,400,000
Contingent consideration fair value adjustments	(14,700,000)	(500,000)	(10,100,000)	400,000
Restructuring and divestiture charges	1,600,000	2,900,000	3,000,000	3,900,000
Operating expenses	289,000,000	239,400,000	583,900,000	548,400,000
Income from operations	796,800,000	156,400,000	1,682,200,000	281,200,000
Interest income	300,000	1,300,000	700,000	3,500,000
Interest expense	(21,300,000)	(31,300,000)	(49,300,000)	(64,100,000)
Debt extinguishment loss	0	0	(21,600,000)	0
Other income (expense), net	4,700,000	(7,500,000)	900,000	(4,200,000)
Income before income taxes	780,500,000	118,900,000	1,612,900,000	216,400,000
Provision (benefit) for income taxes	161,100,000	24,100,000	340,100,000	(264,300,000)
Net income	619,400,000	94,800,000	1,272,800,000	480,700,000
Net loss attributable to noncontrolling interest	(500,000)	(1,500,000)	(1,500,000)	(1,800,000)
Net income attributable to Hologic	$ 619,900,000	$ 96,300,000	$ 1,274,300,000	$ 482,500,000
Net income per common share attributable to Hologic:
Basic (in usd per share)	$ 2.40	$ 0.37	$ 4.93	$ 1.82
Diluted (in usd per share)	$ 2.38	$ 0.36	$ 4.88	$ 1.81
Weighted average number of shares outstanding:
Basic (in shares)	258,473	263,238	258,539	265,566
Diluted (in shares)	260,749	264,506	261,267	267,114

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Statement of Comprehensive Income [Abstract]
Net income	$ 619.4	$ 94.8	$ 1,272.8	$ 480.7
Changes in foreign currency translation adjustment	(9.4)	(5.4)	8.4	2.9
Changes in value of hedged interest rate swaps and interest rate caps, net of tax of $1.4 and $1.2 for the three and six months ended March 27, 2021 and $(8.1) and $(6.4) for the three and six months ended March 28, 2020.	4.3	(25.2)	5	(21.2)
Loss reclassified from accumulated other comprehensive loss to the statements of income	0	0.4	0.5	1.7
Other comprehensive (loss) income	(5.1)	(30.2)	13.9	(16.6)
Comprehensive income	614.3	64.6	1,286.7	464.1
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest	0.5	1.5	1.5	1.8
Comprehensive Income	$ 614.8	$ 66.1	$ 1,288.2	$ 465.9

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Loss (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Statement of Comprehensive Income [Abstract]
Change in value of hedged interest rate swap and interest rate cap, tax	$ 1.4	$ (8.1)	$ 1.2	$ (6.4)

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 27, 2021	Sep. 26, 2020
Current assets:
Cash less assets held for sale	$ 816.4	$ 701
Accounts receivable, less reserves of $41.7 and $31.6, respectively	1,212.3	1,028.9
Inventories	456.2	395.1
Prepaid Income Taxes-Current	85.4	38.8
Prepaid expenses and other current assets	92.1	58.5
Total current assets	2,662.4	2,222.3
Property, plant and equipment, net	533.6	491.5
Intangible assets, net	1,447.6	1,307.5
Goodwill	2,857.2	2,657.9
Other assets	543.2	516.6
Total assets	8,044	7,195.8
Current liabilities:
Current portion of long-term debt	74.9	324.9
Accounts payable	225.1	178.8
Accrued expenses	534.9	547.6
Deferred revenue	198.5	186.1
Current portion of capital lease obligations	3	1.9
Total current liabilities	1,036.4	1,239.3
Long-term debt, net of current portion	2,672.1	2,713.9
Finance lease obligations - long term	23.6	17.4
Deferred Income Tax Liabilities, Net	229.8	201.8
Deferred revenue	13.4	12.9
Other long-term liabilities	273.7	303.2
Stockholders’ equity:
Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued	0	0
Common stock, $0.01 par value –750,000 shares authorized; 296,887 and 295,107 shares issued, respectively	3	2.9
Additional paid-in-capital	5,927.1	5,904.8
Accumulated deficit	(298.9)	(1,573.2)
Treasury stock, at cost – 40,682 and 37,609 shares, respectively	(1,801)	(1,579.6)
Accumulated other comprehensive loss	(35.8)	(49.7)
Total Hologic's stockholders’ equity	3,794.4	2,705.2
Stockholders' Equity Attributable to Noncontrolling Interest	0.6	2.1
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	3,795	2,707.3
Total liabilities and stockholders’ equity	$ 8,044	$ 7,195.8

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Mar. 27, 2021	Sep. 26, 2020
Statement of Financial Position [Abstract]
Accounts receivable, reserves	$ 41.7	$ 31.6
Preferred stock, par value (in dollars per share)	$ 10,000	$ 10,000
Preferred stock, authorized (in shares)	1,623,000,000	1,623,000,000
Preferred stock, issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 10,000	$ 10,000
Common stock, authorized (in shares)	750,000,000,000	750,000,000,000
Common stock, issued (in shares)	296,887,000,000	295,107,000,000
Treasury stock (in shares)	40,682,000,000	37,609,000,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Total	Treasury Stock	Share Repurchase ProgramTreasury Stock
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount	$ 0
Noncontrolling Interest, Increase from Business Combination	8,600,000
Balance (in shares) at Sep. 28, 2019		292,323				24,638
Beginning balance at Sep. 28, 2019	2,115,700,000	$ 2,900,000	$ 5,769,800,000	$ (2,688,700,000)	$ (42,300,000)	$ (926,000,000)
Beginning balance (Accounting Standards Update 2018-01 [Member]) at Sep. 28, 2019				300,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		540
Exercise of stock options			13,800,000
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)		476
Vesting of restricted stock units, net of shares withheld for employee taxes			(10,900,000)
Stock-based compensation expense			18,100,000
Net income	385,800,000
Other comprehensive income activity					13,600,000
Repurchase of common stock (in shares)						1,545	3,279
Repurchase of common stock	(80,900,000)					$ (80,900,000)	$ 164,000,000
Accelerated share repurchase agreement						$ (41,000,000)
Balance (in shares) at Dec. 28, 2019		293,339				29,462
Ending balance at Dec. 28, 2019		$ 2,900,000	5,749,800,000	(2,302,300,000)	(28,700,000)	$ (1,170,900,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss attributable to noncontrolling interest	(300,000)
Net income	386,100,000
Accelerated share repurchase agreement	(205,000,000)
Payments to Noncontrolling Interests	(1,400,000)
Balance (in shares) at Sep. 28, 2019		292,323				24,638
Beginning balance at Sep. 28, 2019	2,115,700,000	$ 2,900,000	5,769,800,000	(2,688,700,000)	(42,300,000)	$ (926,000,000)
Beginning balance (Accounting Standards Update 2018-01 [Member]) at Sep. 28, 2019				300,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	480,700,000
Balance (in shares) at Mar. 28, 2020		294,142				35,941
Ending balance at Mar. 28, 2020		$ 2,900,000	5,827,600,000	(2,206,000,000)	(58,900,000)	$ (1,479,500,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss attributable to noncontrolling interest	(1,800,000)
Net income	482,500,000
Payments to Noncontrolling Interests	(1,700,000)
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount	6,900,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	2,257,700,000
Balance (in shares) at Dec. 28, 2019		293,339				29,462
Beginning balance at Dec. 28, 2019		$ 2,900,000	5,749,800,000	(2,302,300,000)	(28,700,000)	$ (1,170,900,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		503
Exercise of stock options			13,900,000
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)		86
Vesting of restricted stock units, net of shares withheld for employee taxes			(1,600,000)
Common stock issued under the employee stock purchase plan (in shares)		214
Common stock issued under the employee stock purchase plan			8,800,000
Stock-based compensation expense			15,700,000
Net income	94,800,000
Other comprehensive income activity					(30,200,000)
Repurchase of common stock (in shares)						5,851	628
Repurchase of common stock						$ (267,600,000)	$ 41,000,000
Accelerated share repurchase agreement						$ 41,000,000
Balance (in shares) at Mar. 28, 2020		294,142				35,941
Ending balance at Mar. 28, 2020		$ 2,900,000	5,827,600,000	(2,206,000,000)	(58,900,000)	$ (1,479,500,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss attributable to noncontrolling interest	(1,500,000)
Net income	96,300,000
Accelerated share repurchase agreement	0
Payments to Noncontrolling Interests	(300,000)
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount	5,100,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	2,091,200,000
Exercise of stock options (in shares)		533
Exercise of stock options			14,400,000
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)		9
Vesting of restricted stock units, net of shares withheld for employee taxes			(200,000)
Stock-based compensation expense			19,900,000
Net income	136,400,000
Other comprehensive income activity					(3,000,000)
Balance (in shares) at Jun. 27, 2020		294,684				35,941
Ending balance at Jun. 27, 2020		$ 2,900,000	5,861,700,000	(2,068,100,000)	(61,900,000)	$ (1,479,500,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss attributable to noncontrolling interest	(1,500,000)
Net income	137,900,000
Payments to Noncontrolling Interests	(100,000)
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount	3,500,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	2,258,600,000
Exercise of stock options (in shares)		185
Exercise of stock options			6,200,000
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)		40
Vesting of restricted stock units, net of shares withheld for employee taxes			(1,500,000)
Common stock issued under the employee stock purchase plan (in shares)		198
Common stock issued under the employee stock purchase plan			8,800,000
Stock-based compensation expense			29,600,000
Net income	493,500,000
Other comprehensive income activity					12,200,000
Repurchase of common stock (in shares)						1,668
Repurchase of common stock						$ (100,100,000)
Balance (in shares) at Sep. 26, 2020		295,107				37,609
Ending balance at Sep. 26, 2020	2,705,200,000	$ 2,900,000	5,904,800,000	(1,573,200,000)	(49,700,000)	$ (1,579,600,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss attributable to noncontrolling interest	(1,400,000)
Net income	494,900,000
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount	2,100,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	2,707,300,000
Exercise of stock options (in shares)		490
Exercise of stock options			18,400,000
Change in par value	100,000
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)		936
Vesting of restricted stock units, net of shares withheld for employee taxes	(46,400,000)		(46,500,000)
Stock-based compensation expense			18,600,000
Net income	653,400,000
Other comprehensive income activity					19,000,000
Repurchase of common stock (in shares)						1,469
Repurchase of common stock	(101,300,000)					$ (101,300,000)
Balance (in shares) at Dec. 26, 2020		296,533				39,078
Ending balance at Dec. 26, 2020		$ 3,000,000	5,895,300,000	(918,800,000)	(30,700,000)	$ (1,680,900,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss attributable to noncontrolling interest	(1,000,000)
Net income	654,400,000
Balance (in shares) at Sep. 26, 2020		295,107				37,609
Beginning balance at Sep. 26, 2020	2,705,200,000	$ 2,900,000	5,904,800,000	(1,573,200,000)	(49,700,000)	$ (1,579,600,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	1,272,800,000
Balance (in shares) at Mar. 27, 2021		296,887				40,682
Ending balance at Mar. 27, 2021	3,794,400,000	$ 3,000,000	5,927,100,000	(298,900,000)	(35,800,000)	$ (1,801,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss attributable to noncontrolling interest	(1,500,000)
Net income	1,274,300,000
Payments to Noncontrolling Interests	0
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount	1,100,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	3,269,000,000
Balance (in shares) at Dec. 26, 2020		296,533				39,078
Beginning balance at Dec. 26, 2020		$ 3,000,000	5,895,300,000	(918,800,000)	(30,700,000)	$ (1,680,900,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		146
Exercise of stock options			5,800,000
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)		17
Vesting of restricted stock units, net of shares withheld for employee taxes	(300,000)		(300,000)
Common stock issued under the employee stock purchase plan (in shares)		191
Common stock issued under the employee stock purchase plan			9,200,000
Stock-based compensation expense			17,100,000
Net income	619,400,000
Other comprehensive income activity					(5,100,000)
Repurchase of common stock (in shares)						1,604
Repurchase of common stock	(120,100,000)					$ (120,100,000)
Balance (in shares) at Mar. 27, 2021		296,887				40,682
Ending balance at Mar. 27, 2021	3,794,400,000	$ 3,000,000	$ 5,927,100,000	$ (298,900,000)	$ (35,800,000)	$ (1,801,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss attributable to noncontrolling interest	(500,000)
Net income	619,900,000
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount	600,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 3,795,000,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Mar. 27, 2021	Mar. 28, 2020
OPERATING ACTIVITIES
Net income	$ 1,272,800,000	$ 480,700,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	41,500,000	42,300,000
Amortization of acquired intangibles	146,500,000	145,800,000
Stock-based compensation expense	35,600,000	33,800,000
Deferred income taxes	(23,500,000)	(44,200,000)
Intangible asset and equipment impairment charges	0	30,200,000
Debt extinguishment loss	21,600,000	0
Other adjustments and non-cash items	18,900,000	14,800,000
Changes in operating assets and liabilities, excluding the effect of acquisitions:
Accounts receivable	(171,400,000)	(300,000)
Inventories	(46,000,000)	(33,300,000)
Prepaid income taxes	(46,600,000)	(27,700,000)
Prepaid expenses and other assets	(36,700,000)	(317,600,000)
Accounts payable	32,800,000	(47,900,000)
Accrued expenses and other liabilities	(50,100,000)	(50,800,000)
Deferred revenue	6,800,000	5,800,000
Net cash provided by operating activities	1,202,200,000	231,600,000
INVESTING ACTIVITIES
Acquisition of businesses, net of cash acquired	(440,000,000)	(43,200,000)
Proceeds From Sale Of Business	0	142,700,000
Capital expenditures	(51,700,000)	(29,600,000)
Increase in equipment under customer usage agreements	(27,800,000)	(33,500,000)
Purchase of insurance contracts	1,600,000	2,400,000
Purchase of intellectual property	(6,500,000)	0
Other activity	(500,000)	(1,400,000)
Net cash (used in) provided by investing activities	(528,100,000)	32,600,000
FINANCING ACTIVITIES
Repayment of long-term debt	(37,500,000)	(27,100,000)
Proceeds from Notes Payable	950,000,000	0
Repayments of Senior Debt	(970,800,000)	0
Proceeds from revolving credit line	0	750,000,000
Repayment under revolving credit line	(250,000,000)	0
Proceeds from accounts receivable securitization agreement	0	16,000,000
Repayments of Accounts Receivable Securitization	0	(250,000,000)
Payments to Noncontrolling Interests	0	(1,700,000)
Payment of deferred acquisition consideration	0	(24,300,000)
Payment of debt issuance costs	(13,700,000)	0
Repurchase of common stock	(221,400,000)	(553,500,000)
Proceeds from issuance of common stock pursuant to employee stock plans	33,600,000	36,600,000
Payment of minimum tax withholdings on net share settlements of equity awards	(46,700,000)	(12,500,000)
Payments under finance lease obligations	(900,000)	(800,000)
Net cash used in financing activities	(557,400,000)	(67,300,000)
Effect of exchange rate changes on cash and cash equivalents	(1,300,000)	1,100,000
Net increase in cash and cash equivalents	115,400,000	198,000,000
Cash and cash equivalents, beginning of period	701,000,000	601,800,000
Cash and cash equivalents, end of period	$ 816,400,000	$ 799,800,000

Basis of Presentation

Basis of Presentation	3 Months Ended
	Dec. 26, 2020
Basis of Presentation [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements of Hologic, Inc. (“Hologic” or the “Company”) presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission (the “SEC”) for quarterly reports on Form 10-Q and do not include all of the information and disclosures required by U.S. generally accepted accounting principles (“GAAP”) for annual financial statements. These financial statements should be read in conjunction with the consolidated financial statements and related notes for the fiscal year ended September 26, 2020 included in the Company’s Form 10-K filed with the SEC on November 17, 2020. In the opinion of management, the financial statements and notes contain all adjustments (consisting of normal recurring accruals and all other necessary adjustments) considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the periods presented. The consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The preparation of financial statements in conformity with GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from management’s estimates if past experience or other assumptions do not turn out to be substantially accurate. Operating results for the three and six months ended March 27, 2021 are not necessarily indicative of the results to be expected for any other interim period or the entire fiscal year ending September 25, 2021. Recently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-13, Financial Instruments – Credit Losses (Topic 326) . The purpose of ASU 2016-13 is to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses over the lifetime of the financial asset. As a result, credit losses are recorded when financial assets are established if credit losses are expected over the asset's contractual life. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company adopted the standard during the first quarter of fiscal 2021. The adoption of ASU 2016-13 did not have a material effect on the Company's consolidated financial statements. See Note 5 for additional information. In November 2019, the FASB issued ASU No. 2019-08, Compensation - Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606) . This ASU identifies, evaluates, and improves areas of GAAP for which cost and complexity can be reduced while maintaining or improving the usefulness of the information provided. The amendments in this Update expanded the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The Company adopted this ASU in the first quarter of fiscal 2021, which did not have a material effect on the Company's financial statements. Subsequent Events Consideration The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence for certain estimates or to identify matters that may require additional disclosure. Subsequent events have been evaluated as required. There were no material recognized subsequent events affecting the unaudited consolidated financial statements as of and for the three and six months ended March 27, 2021. There was one unrecognized subsequent event related to the acquisition of Mobidiag Oy ("Mobidiag"). On April 8, 2021, the Company announced that it had entered into an agreement to acquire Mobidiag for a purchase price of approximately $795 million. The closing is subject to certain regulatory approvals and other customary closing conditions. Mobidiag, located in Finland and France, manufactures molecular diagnostic solutions for gastrointestinal infections, antimicrobial resistance management and other infections. The Company expects this acquisition to close in the fourth quarter of fiscal 2021.

Leases

Leases	6 Months Ended
	Mar. 27, 2021
Leases [Abstract]
Leases	LeasesLessor Activity - Leases where Hologic is the LessorCertain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for disposables, reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. Sales-type leases are immaterial. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented less than 5% of the Company's consolidated revenue for all periods presented.
Leases	LeasesLessor Activity - Leases where Hologic is the LessorCertain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for disposables, reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. Sales-type leases are immaterial. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented less than 5% of the Company's consolidated revenue for all periods presented.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Mar. 27, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]	Fair Value Measurements Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis The Company has investments in derivative instruments comprised of an interest rate swap, forward foreign currency contracts and foreign currency option contracts, which are valued using analyses obtained from independent third party valuation specialists based on market observable inputs, representing Level 2 assets. The fair values of these derivative contracts represent the estimated amounts the Company would receive or pay to terminate the contracts. Refer to Note 9 for further discussion and information on derivative instruments. Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following at March 27, 2021: Fair Value at Reporting Date Using Balance as of March 27, 2021 Quoted Prices in Significant Significant Assets: Foreign currency option contracts $ 1.1 $ — $ 1.1 $ — Total $ 1.1 $ — $ — $ — Liabilities: Contingent consideration $ 71.7 $ — $ — $ 71.7 Interest rate swap 24.9 — 24.9 — Forward foreign currency contracts 3.0 — 3.0 — Total $ 99.6 $ — $ 27.9 $ 71.7 Liabilities Measured and Recorded at Fair Value on a Recurring Basis Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of contingent consideration liabilities, during the three and six month periods ended March 27, 2021 and March 28, 2020 were as follows: Three Month Ended Six Months Ended March 27, 2021 March 28, 2020 March 27, 2021 March 28, 2020 Balance at beginning of period $ 86.4 $ 10.0 $ 81.8 $ 9.1 Contingent consideration recorded at acquisition — 0.9 — 0.9 Fair value adjustments (14.7) (0.5) (10.1) 0.4 Payments/Accruals — (9.6) — (9.6) Balance at end of period $ 71.7 $ 0.8 $ 71.7 $ 0.8 Assets Measured and Recorded at Fair Value on a Nonrecurring Basis The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets are comprised of equity investments and long-lived assets, including property, plant and equipment, intangible assets and goodwill. There were no such remeasurements to equity investments in the three and six months ended March 27, 2021 and March 28, 2020. During the first quarter of fiscal 2020, the Company's Medical Aesthetics division met the criteria to be classified as assets-held-for sale, and the Company recorded a $30.2 million loss to record the asset group at its fair value less costs to sell. This is a level 1 measurement. See Note 7 for additional information. Disclosure of Fair Value of Financial Instruments The Company’s financial instruments mainly consist of cash and cash equivalents, accounts receivable, equity investments, an interest rate swap, forward foreign currency contracts, foreign currency option contracts, insurance contracts, accounts payable and debt obligations. The carrying amounts of the Company’s cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term nature of these instruments. The Company’s interest rate swap, forward foreign currency contracts and foreign currency option contracts are recorded at fair value. The carrying amount of the insurance contracts are recorded at the cash surrender value, as required by GAAP, which approximates fair value. The Company believes the carrying amounts of its cost-method equity investments approximate fair value.

Business Combinations

Business Combinations	6 Months Ended
	Mar. 27, 2021
Business Combinations [Abstract]
Business Combinations	Business Combinations Fiscal 2021 Acquisitions Biotheranostics On February 22, 2021, the Company completed the acquisition of Biotheranostics, Inc. ("Biotheranostics"), for a purchase price of $232.5 million. Biotheranostics, located in San Diego, California, manufactures molecular diagnostic tests for breast and metastatic cancers and performs the lab testing procedures at its facility. Biotheranostics' results of operations are reported in the Company's Diagnostics reportable segment from the date of acquisition and its revenues are reported within Service and other revenue in the Company's consolidated statement of income and within service revenue in our disclosure of disaggregated revenue in Note 2. The total purchase price was allocated to Biotheranostics' preliminary tangible and identifiable intangible assets and liabilities based on the estimated fair values as of February 22, 2021, as set forth below. Cash $ 9.6 Accounts receivable 2.9 Other assets 6.5 Accounts payable and accrued expenses (8.2) Other liabilities (8.1) Identifiable intangible assets: Developed technology 160.3 Trade names 2.1 Deferred income taxes, net (18.4) Goodwill 85.8 Purchase Price $ 232.5 In performing the preliminary purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of Biotheranotics' business. The allocation of the purchase price is preliminary as the Company continues to gather information supporting the acquired assets and liabilities, the estimation of the fair value of the identifiable intangible assets, and income taxes. As part of the preliminary purchase price allocation, the Company determined the identifiable intangible assets are developed technology and trade names. The preliminary fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using a 18.0% rate. The cash flows were based on estimates used to price the transaction, and the discount rate applied was benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The weighted average life of developed technology and trade names is 10 years. The preliminary calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. Factors contributing to the recognition of the preliminary amount of goodwill were primarily based on anticipated synergistic benefits of adding Biotheranostics' CLIA (Clinical Laboratory Improvement Amendments) lab to the Company's portfolio of offerings and of utilizing Diagnostic's marketing and regulatory expertise to drive adoption and revenue growth. None of the goodwill is expected to be deductible for income tax purposes. Diagenode On March 1, 2021, the Company completed the acquisition of Diagenode SA ("Diagenode") for a purchase price of $153.4 million. Diagenode, located in Belgium, is a developer and manufacturer of molecular diagnostic assays based on PCR (polymerase chain reaction) technology to detect infectious diseases of bacterial, viral or parasite origin. Diagenode's results of operations are reported in the Company's Diagnostics reportable segment from the date of acquisition. The total purchase price was allocated to Diagenode's preliminary tangible and identifiable intangible assets and liabilities based on the estimated fair values as of March 1, 2021, as set forth below. Cash $ 5.6 Accounts receivable 9.1 Inventory 9.2 Other assets 13.8 Accounts payable and accrued expenses (9.2) Other liabilities (12.9) Identifiable intangible assets: Developed technology 69.8 Customer relationships 9.2 Deferred income taxes, net (19.3) Goodwill 78.1 Purchase Price $ 153.4 In performing the preliminary purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of Diagenode's business. The allocation of the purchase price is preliminary as the Company continues to gather information supporting the acquired assets and liabilities, the estimation of the fair value of the identifiable intangible assets, and income taxes. As part of the preliminary purchase price allocation, the Company determined the identifiable intangible assets are developed technology and customer relationships. The preliminary fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using a 14.5% rate for developed technology and a 13.5% rate for customer relationships. The cash flows were based on estimates used to price the transaction, and the discount rate applied was benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The weighted average life of developed technology and customer relationships is 10 years. The preliminary calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. Factors contributing to the recognition of the preliminary amount of goodwill were based on anticipated synergistic benefits of Diagenode's products broadening the Diagnostics portfolio of molecular diagnostics products primarily in the transplant and acute care gastrointestinal and respiratory space as customers seek a broader menu of tests, utilizing Diagnostic's sales force to drive menu expansion and revenue growth and gaining additional PCR assay development expertise. None of the goodwill is expected to be deductible for income tax purposes. Somatex Medical Technologies On December 30, 2021, the Company completed the acquisition of Somatex Medical Technologies GmbH ("Somatex") for a purchase price of $62.8 million. Somatex, located in Germany, is a manufacturer of biopsy site markers, including the Tumark product line of tissue markers, which were distributed by the Company in the U.S. prior to the acquisition. The allocation of the purchase price is based on the Company's preliminary valuation, and it allocated $38.0 million to the preliminary value of developed technology, $1.2 million to customer relationships, $0.9 million to trade names and $32.0 million to goodwill. The remaining $9.3 million of the purchase price was allocated to the net acquired tangible assets and liabilities. The allocation of the purchase price is preliminary as the Company continues to gather information supporting the acquired assets and liabilities. Somatex' results of operations are reported in the Company's Breast Health reportable segment from the date of acquisition. NXC Imaging On September 28, 2020, the Company completed the acquisition of assets from NXC Imaging, for a purchase price of $5.6 million. NXC Imaging was a long-standing distributor of the Company's Breast and Skeletal products in the U.S. Based on the Company's preliminary valuation, the majority of the purchase price was allocated to a customer relationships intangible asset with a useful life of 5 years. The allocation of the purchase price is preliminary as the Company continues to gather information supporting the acquired assets and liabilities. Fiscal 2020 Acquisitions Acessa Health On August 23, 2020, the Company completed the acquisition of Acessa Health, Inc. ("Acessa") for a purchase price of $161.3 million, which included a hold-back of $3.0 million that was paid in January 2021, and contingent consideration, which the Company estimated the fair value to be $81.8 million as of the measurement date. Acessa, located in Austin, Texas, manufactures and markets its ProVu system, a laparoscopic radio frequency ablation system for use in treatment of uterine fibroids. Acessa's results of operations are reported in the Company's GYN Surgical reportable segment from the date of acquisition. The contingent payments are based on a multiple of annual incremental revenue growth over a three-year period ending annually in December. There is no maximum earnout. Pursuant to ASC 805, Business Combinations , the Company recorded its estimate of the fair value of the contingent consideration liability utilizing the Monte Carlo simulation based on future revenue projections of Acessa, comparable companies revenue growth rates, implied volatility and applying a risk adjusted discount rate. Each quarter the Company will be required to remeasure the fair value of the liability as assumptions change and such adjustments will be recorded in operating expenses. This fair value measurement was based on significant inputs not observable in the market and thus represented a Level 3 measurement as defined in ASC 820, Fair Value Measurements . This fair value measurement is directly impacted by the Company's estimate of future incremental revenue growth of the business. Accordingly, if actual revenue growth is higher or lower than the estimates within the fair value measurement, the Company would record additional charges or benefits, respectively. For the three and six month periods ended March 27, 2021, the Company remeasured the contingent consideration liability and decreased the contingent consideration liability by $14.7 million and $10.1 million, respectively, to record the liability at fair value as of March 27, 2021. The reduction in fair value was primarily due to a decrease in forecasted revenues over the measurement period. The total purchase price was allocated to Acessa's preliminary tangible and identifiable intangible assets and liabilities based on the estimated fair values as of August 23, 2020, as set forth below. Cash $ 1.2 Inventory 4.0 Other assets 4.4 Accounts payable and accrued expenses (4.7) Identifiable intangible assets: Developed technology 127.0 Trade names 1.2 Deferred income taxes, net (20.2) Goodwill 48.4 Purchase Price $ 161.3 In performing the preliminary purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of Acessa's business. The allocation of the purchase price is preliminary as the Company continues to gather information supporting the acquired assets and liabilities, primarily taxes. As part of the preliminary purchase price allocation, the Company determined the identifiable intangible assets are developed technology and trade names. The preliminary fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using a 18.0% rate. The cash flows were based on estimates used to price the transaction, and the discount rate applied was benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The weighted average life of developed technology and trade names is 10 years. The preliminary calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. Factors contributing to the recognition of the preliminary amount of goodwill were based on anticipated synergistic benefits of Acessa's products being complementary to the GYN Surgical portfolio of products and utilizing the GYN Surgical's sales force to drive adoption and revenue growth. None of the goodwill is expected to be deductible for income tax purposes. Health Beacons On February 3, 2020, the Company completed the acquisition of Health Beacons, Inc. ("Health Beacons"), for a purchase price of $19.7 million, which included hold-backs of $2.3 million that are payable up to eighteen months from the date of acquisition. Health Beacons manufactures the LOCalizer product. Based on the Company's valuation, it allocated $10.7 million to developed technology and $6.2 million to goodwill. The remaining $2.8 million of the purchase price was allocated to acquired tangible assets and liabilities. Health Beacons' results of operations are reported in the Company's Breast Health reportable segment from the date of acquisition. Alpha Imaging On December 30, 2019, the Company completed the acquisition of assets from Alpha Imaging, LLC ("Alpha Imaging"), for a purchase price of $18.0 million, which included a hold-back of $1.0 million and contingent consideration which the Company has estimated at $0.9 million. The contingent consideration was payable upon shipment of backlog orders entered into by Alpha Imaging prior to the acquisition. Alpha Imaging was a long-standing distributor of the Company's Breast and Skeletal products in the U.S. The majority of the purchase price was allocated to a customer relationships intangible asset with a useful life of 5 years. SuperSonic Imagine On August 1, 2019, the Company purchased 46% of the outstanding shares of SuperSonic Imagine ("SSI") for $18.2 million. SSI is a public company located in Aix-en-Provence, France that manufactures and markets ultrasound medical imaging equipment. In September 2019, the Company launched a cash tender offer to acquire the remaining outstanding shares for a price of €1.50 per share in cash. The Company determined that SSI was a Variable Interest Entity (“VIE”) but it was not the primary beneficiary as it was not a party to the initial design of the entity nor did it have control over SSI's operations until November 21, 2019 when the Company's ownership of SSI's voting stock exceeded 50%. Accordingly, the Company initially accounted for this investment under the equity method of accounting. On November 21, 2019, the Company acquired an additional 7.6 million shares of SSI for $12.6 million. As a result, the Company's ownership interest increased to approximately 78% of the outstanding common shares of SSI at November 21, 2019, and it now controlled SSI's voting interest and operations. The Company performed purchase accounting as of November 21, 2019 and beginning on that date the financial results of SSI are included within the Company's consolidated financial statements, specifically the Breast Health reportable segment. The Company remeasured the initial investment of 46% of the outstanding shares of SSI to its fair value at the acquisition date, resulting in a gain of $3.2 million recorded to other income (expense), net in the first quarter of fiscal 2020. The total accounting purchase price was $69.3 million, which consisted of $17.9 million for the equity method investment in SSI, $12.6 million for shares acquired on November 21, 2019, $30.2 million for loans the Company provided to SSI prior to the acquisition to pay-off pre-existing loans and fund operations that are considered forgiven, and $8.6 million representing the fair value of the noncontrolling interest as of November 21, 2019. The Company purchased an additional 1.1 million outstanding shares in fiscal 2020 for $1.8 million, and as of March 27, 2021, the Company owned approximately 80% of the outstanding shares of SSI. The total purchase price was allocated to SSI's tangible and identifiable intangible assets and liabilities based on the estimated fair values of those assets as of November 21, 2019, as set forth below. Cash $ 2.6 Accounts receivable 7.1 Inventory 10.0 Property, plant and equipment 6.5 Other assets 4.3 Accounts payable and accrued expenses (24.5) Deferred revenue (1.8) Short and long-term debt (8.8) Other liabilities (3.8) Identifiable intangible assets: Developed technology 38.3 Customer relationships 4.0 Trade names 3.0 Deferred income taxes, net (1.9) Goodwill 34.3 Purchase Price $ 69.3 In performing the purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of SSI's business. As part of the purchase price allocation, the Company determined the identifiable intangible assets were developed technology, customer relationships, and trade names. The fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using a 12.0% rate. The cash flows were based on estimates used to price the transaction, and the discount rates applied were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The weighted average life for the developed technology is 9 years, customer relationships is 9 years and trade names is 8.6 years. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. Factors contributing to the recognition of the amount of goodwill were based on anticipated synergistic benefits of SSI's products being complementary to Breast Health's 3D mammography systems and using the Company's existing U.S. sales force as SSI's presence in the U.S. is limited. None of the goodwill is expected to be deductible for income tax purposes.

Trade Receivables and Allowance

Trade Receivables and Allowance for Credit Losses	6 Months Ended
	Mar. 27, 2021
Receivables [Abstract]
Trade Receivables and Allowance for Credit Losses	Trade Receivables and Allowance for Credit Losses Effective September 27, 2020, the Company adopted Topic 326, which requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The expected credit losses are developed using an estimated loss rate method that considers historical collection experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The estimated loss rates are applied to trade receivables with similar risk characteristics such as the length of time the balance has been outstanding and the location of the customer. In certain instances, the Company may identify individual trade receivable assets that do not share risk characteristics with other trade receivables, in which case the Company records its expected credit losses on an individual asset basis. For example, potential adverse changes to customer liquidity from new macroeconomic events, such as the COVID-19 pandemic, must be taken into consideration. To date, the Company has not experienced significant customer payment defaults, or identified other significant collectability concerns as a result of the pandemic. In connection with assessing credit losses for individual trade receivable assets, the Company considers significant factors relevant to collectability including those specific to the customer such as bankruptcy, length of time an account is outstanding, and the liquidity and financial position of the customer. If a trade receivable asset is evaluated on an individual basis, the Company excludes those assets from the portfolios of trade receivables evaluated on a collective basis. The following is a rollforward of the allowance for credit losses as of March 27, 2021 compared to March 28, 2020: Balance at Credit Loss Reclassified as Assets held for sale Write- Balance at Six Months Ended March 27, 2021 $ 31.6 $ 12.5 $ — $ (2.4) $ 41.7 March 28, 2020 $ 17.8 $ 5.5 $ (5.9) $ (1.4) $ 16.0

Disposition

Disposition	3 Months Ended
	Mar. 27, 2021
Discontinued Operations and Disposal Groups [Abstract]
Dispositions	Disposition - Sale of Medical Aesthetics On November 20, 2019, the Company entered into a definitive agreement to sell its Medical Aesthetics business to Clayton Dubilier & Rice ("CD&R") for a sales price of $205.0 million in cash, less certain adjustments. The sale was completed on December 30, 2019, and the Company received cash proceeds of $153.4 million in the second quarter of fiscal 2020. The sale price was subject to adjustment pursuant to the terms of the definitive agreement, and the parties agreed to a final sales price of $150.0 million in the fourth quarter of fiscal 2020. The Company agreed to provide certain transition services for three to fifteen months, depending on the nature of the service. The Company also agreed to indemnify CD&R for certain legal and tax matters that existed as of the date of disposition. In connection with its accounting for the sale, the Company recorded indemnification liabilities of $10.9 million within accrued expenses associated with its obligations under the sale agreement. As a result of this transaction, the Medical Aesthetics asset group was designated as assets held-for-sale in the first quarter of fiscal 2020. Pursuant to ASC 360, asset groups under this designation are required to be recorded at fair value less costs to sell. The Company determined that this disposal did not qualify as a discontinued operation as the sale of the Medical Aesthetics business was deemed to not be a strategic shift having or will have a major effect on the Company's operations and financial results. Based on the terms in the agreement of the sales price and formula for net working capital and related adjustments, its estimate of the fair value for transition services and the amount that must be carved out of the sale proceeds, and liabilities the Company will retain or for which it has agreed to indemnify CD&R, the Company recorded an impairment charge of $30.2 million in the first quarter of fiscal 2020. The impairment charge was allocated to Medical Aesthetics long-lived assets, of which $25.8 million was allocated to cost of product revenues and $4.4 million to operating expenses. In the first quarter of fiscal 2020, this business incurred a loss from operations of $46.5 million, which excludes corporate allocations. The operating expenses include only those that were incurred directly by and were retained by the disposed business. The Company will continue to incur expenses related to this business under the indemnification provisions

Borrowings and Credit Arrangeme

Borrowings and Credit Arrangements	3 Months Ended
	Sep. 28, 2019
Debt Disclosure [Abstract]
Borrowings and Credit Arrangements	Borrowings and Credit Arrangements The Company’s borrowings consisted of the following: March 27, September 26, Current debt obligations, net of debt discount and deferred issuance costs: Term Loan $ 74.9 $ 74.9 Revolver — 250.0 Total current debt obligations $ 74.9 $ 324.9 Long-term debt obligations, net of debt discount and issuance costs: Term Loan 1,343.6 1,379.9 2025 Senior Notes — 939.4 2028 Senior Notes 395.0 394.6 2029 Senior Notes 933.5 — Total long-term debt obligations $ 2,672.1 $ 2,713.9 Total debt obligations $ 2,747.0 $ 3,038.8 2018 Amended and Restated Credit Agreement On December 17, 2018, the Company and certain of its subsidiaries refinanced its term loan and revolving credit facility by entering into an Amended and Restated Credit and Guaranty Agreement as of December 17, 2018 (the "2018 Credit Agreement") with Bank of America, N.A. in its capacity as Administrative Agent, Swing Line Lender and L/C Issuer, and certain other lenders. The 2018 Credit Agreement amended and restated the Company's prior credit and guaranty agreement dated as of October 3, 2017 (the "2017 Credit Agreement"). As of March 27, 2021, the principal amount outstanding of the term loan under the 2018 Credit Agreement (the "Term Loan") was $1.4 billion. The Term Loan bears interest at an annual rate equal to the Eurocurrency Rate (i.e., the LIBOR rate) plus an Applicable Rate, which was 1.00% as of March 27, 2021. The Company also has a $1.5 billion revolving credit facility (the "Revolver") under the 2018 Credit Agreement. The borrowings of the Revolver bear interest at a rate equal to the LIBOR Daily Floating Rate plus an Applicable Rate, which was 1.00% as of March 27, 2021. In response to the market uncertainties created by the COVID-19 pandemic in March 2020, the Company borrowed $750.0 million under the Revolver, $250.0 million of which was used to pay off amounts outstanding under the asset securitization agreement, in order to have sufficient cash on hand. During the first quarter of fiscal 2021, the Company paid off the remaining outstanding balance of $250.0 million. As of March 27, 2021, the full amount of the Revolver ($1.5 billion) was available to borrow by the Company. Interest expense, weighted average interest rates, and the interest rate at the end of period under the Credit Agreements were as follows: Three Months Ended Six Months Ended March 27, 2021 March 28, 2020 March 27, 2021 March 28, 2020 Interest expense $ 5.3 $ 13.0 $ 11.8 $ 26.6 Weighted average interest rate 1.12 % 2.75 % 1.17 % 2.93 % Interest rate at end of period 1.11 % 2.33 % 1.11 % 2.33 % The 2018 Credit Agreement contains two financial covenants; a total leverage ratio and an interest coverage ratio, both of which are measured as of the last day of each fiscal quarter. These terms, and calculations thereof, are defined in further detail in the 2018 Credit Agreement. As of March 27, 2021, the Company was in compliance with these covenants. Senior Notes On September 28, 2020, the Company completed a private placement of $950 million aggregate principal amount of its 3.250% Senior Notes due 2029 (the "2029 Senior Notes") at an offering price of 100% of the aggregate principal amount of the 2029 Senior Notes. The Company used the net proceeds of the 2029 Senior Notes offering and cash on hand to redeem in full its 4.375% Senior Notes due 2025 (the "2025 Senior Notes") in the aggregate principal amount of $950.0 million on October 15, 2020 at an aggregate redemption price of $970.8 million, including a premium payment $20.8 million. 2025 Senior Notes Immediately prior to redemption in full of the 2025 Senior Notes on October 15, 2020, the total aggregate principal balance of 2025 Senior Notes was $950.0 million. As the Company planned to use the proceeds from the 2029 Senior Notes offering to redeem the 2025 Senior Notes, the Company evaluated the accounting for this transaction under ASC 470, Debt , to determine modification versus extinguishment accounting on a creditor-by-creditor basis. Certain 2025 Senior Note holders either did not participate in this refinancing transaction or reduced their holdings, and these transactions were accounted for as extinguishments. As a result, the Company recorded a debt extinguishment loss in the first quarter of fiscal 2021 of $21.6 million. For the remaining 2025 Senior Notes holders who participated in the refinancing, these transactions were accounted for as modifications because on a creditor-by-creditor basis the present value of the cash flows between the debt instruments before and after the transaction was less than 10%. The Company recorded a portion of the transaction expenses of $5.8 million to interest expense pursuant to ASC 470, subtopic 50-40. The remaining debt issuance costs of $7.9 million and debt discount of $6.4 million related to the modified debt will be amortized over the new term of the 2029 Senior Notes using the effective interest method. 2028 Senior Notes As of March 27, 2021, the Company had 4.625% Senior Notes due 2028 (the "2028 Senior Notes") outstanding in the aggregate principal balance of $400 million. The 2028 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain domestic subsidiaries and mature on February 1, 2028. 2029 Senior Notes As of March 27, 2021, the Company had 2029 Senior Notes outstanding in the aggregate principal balance of $950 million. The 2029 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain domestic subsidiaries. The 2029 Senior Notes mature on February 15, 2029 and bear interest at the rate of 3.250% per year, payable semi-annually on February 15 and August 15 of each year, commencing on February 15, 2021. The Company may redeem the 2029 Senior Notes at any time prior to September 28, 2023 at a price equal to 100% of the aggregate principal amount so redeemed, plus accrued and unpaid interest, if any, to the redemption date and a make-whole premium set forth in the indenture. The Company may also redeem up to 40% of the aggregate principal amount of the 2029 Senior Notes with the net cash proceeds of certain equity offerings at any time and from time to time before September 28, 2023, at a redemption price equal to 103.250% of the aggregate principal amount so redeemed, plus accrued and unpaid interest, if any, to the redemption date. The Company also has the option to redeem the 2029 Senior Notes on or after: September 28, 2023 through September 27, 2024 at 101.625% of par; September 28, 2024 through September 27, 2025 at 100.813% of par; and September 28, 2025 and thereafter at 100% of par. In addition, if the Company undergoes a change of control coupled with a decline in ratings, as provided in the indenture, the Company will be required to make an offer to purchase each holder’s 2029 Senior Notes at a price equal to 101% of their principal amount, plus accrued and unpaid interest, if any, to the repurchase date. The Company evaluated the 2029 Senior Notes for derivatives pursuant to ASC 815 and did not identify any embedded derivatives that require bifurcation. All features were deemed to be clearly and closely related to the host instrument. Interest expense for the 2029 Senior Notes, 2028 Senior Notes and 2025 Senior Notes was as follows: Three Months Ended Six Months Ended March 27, 2021 March 28, 2020 March 27, 2021 March 28, 2020 Interest Rate Interest Expense Interest Expense Interest Expense Interest Expense 2025 Senior Notes 4.375 % $ — $ 10.9 $ 2.3 $ 21.8 2028 Senior Notes 4.625 % 4.8 4.8 9.6 9.6 2029 Senior Notes 3.250 % 8.3 — 16.3 — Total $ 13.1 $ 15.7 $ 28.2 $ 31.4

Derivatives

Derivatives	6 Months Ended
	Mar. 27, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Derivatives Interest Rate Cap - Cash Flow Hedge The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company manages its exposure to some of its interest rate risk through the use of interest rate caps, which are derivative financial instruments. The Company does not use derivatives for speculative purposes. For a derivative that is designated as a cash flow hedge, changes in the fair value of the derivative are recognized in accumulated other comprehensive income ("AOCI") to the extent the derivative is effective at offsetting the changes in the cash flows being hedged until the hedged item affects earnings. To the extent there is any hedge ineffectiveness, changes in fair value relating to the ineffective portion are immediately recognized in earnings in other income (expense), net in the Consolidated Statements of Income. During fiscal 2018, the Company entered into separate interest rate cap agreements with multiple counter-parties to mitigate the interest rate volatility associated with the variable interest rate on amounts borrowed under the term loan feature of its credit facilities (see Note 7). Interest rate cap agreements provide the right to receive cash if the reference interest rate rises above a contractual rate. The aggregate premium paid for these interest rate cap agreements was $3.7 million, which was the initial fair value of the instruments recorded in the Company's financial statements. During fiscal 2019, the Company entered into additional separate interest rate cap agreements with multiple counter-parties to extend the expiration date of its hedges by an additional year. The aggregate premium paid for these interest cap agreements was $1.5 million, which was the initial fair value of the instruments recorded in the Company’s financial statements. The critical terms of the interest rate caps were designed to mirror the terms of the Company’s LIBOR-based borrowings under its Credit Agreement, that has been amended multiple times, and therefore are highly effective at offsetting the cash flows being hedged. The Company designated these derivatives as cash flow hedges of the variability of the LIBOR-based interest payments on $1.0 billion of principal, which ended on December 27, 2019 for the contracts entered into in fiscal 2018, and on December 23, 2020 for the interest rate cap agreements entered into in fiscal 2019. The interest rate cap agreements matured as of December 26, 2020. Interest Rate Swap - Cash Flow Hedge In fiscal 2019, in order to hedge a portion of its variable rate debt beyond the contracted period under interest cap agreements, the Company entered into an interest rate swap contract with an effective date of December 23, 2020 and a termination date of December 17, 2023. The notional amount of this swap is $1.0 billion. The interest rate swap effectively fixes the LIBOR component of the variable interest rate on $1.0 billion of the notional amount under the 2018 Credit Agreement at 1.23%. The critical terms of the interest rate swap are designed to mirror the terms of the Company’s LIBOR-based borrowings under its credit agreement and therefore are highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the LIBOR-based interest payments on $1.0 billion of principal. Therefore, changes in the fair value of the swap are recorded in AOCI. The fair value of this derivative was in a liability position of $24.9 million as of March 27, 2021. Forward Foreign Currency Contracts and Foreign Currency Option Contracts The Company enters into forward foreign currency exchange contracts and foreign currency option contracts to mitigate a portion of its cash balances and certain operational exposures from the impact of changes in foreign currency exchange rates. Such exposures result from the portion of the Company's cash and operations that are denominated in currencies other than the U.S. dollar, primarily the Euro, the UK Pound, the Australian dollar, the Canadian dollar, the Chinese Yuan and the Japanese Yen. These foreign currency exchange contracts are entered into to support transactions made in the ordinary course of business and are not speculative in nature. The contracts are generally for periods of one year or less. The Company did not elect hedge accounting for these contracts; however, the Company may seek to apply hedge accounting in future scenarios. The change in the fair value of these contracts is recognized directly in earnings as a component of other income (expense), net. Realized and unrealized gains and losses from these contracts, which were the only derivative contracts not designated for hedge accounting, for the three and six months ended March 27, 2021 and March 28, 2020, respectively, were as follows: Three Months Ended Six Months Ended March 27, 2021 March 28, 2020 March 27, 2021 March 28, 2020 Amount of realized gain (loss) recognized in income Forward foreign currency contracts $ 3.4 $ 0.1 $ 0.5 $ 0.1 Foreign currency option contracts (1.8) (0.5) (3.0) (0.7) $ 1.6 $ (0.4) $ (2.5) $ (0.6) Amount of unrealized gain (loss) recognized in income Forward foreign currency contracts $ 3.1 $ 2.6 $ (3.5) $ 1.1 Foreign currency option contracts 2.1 1.1 (5.9) (0.4) $ 5.2 $ 3.7 $ (9.4) $ 0.7 Amount of gain (loss) recognized in income Total $ 6.8 $ 3.3 $ (11.9) $ 0.1 As of March 27, 2021, the Company had outstanding forward foreign currency contracts that were not designated for hedge accounting and were used to hedge fluctuations in the U.S. dollar of certain of our cash balances denominated in the Euro and UK pound, as well as forecasted transactions denominated in the Euro, UK pound, Australian Dollar, Canadian Dollar, Chinese Yuan and Japanese Yen with an aggregate notional amount of $415.8 million. As of March 27, 2021, the Company had outstanding foreign currency option contracts that were not designated for hedge accounting and were used to hedge fluctuations in the U.S. dollar of forecasted transactions denominated in the Euro and UK Pound with a notional amount of $133.5 million. Financial Instrument Presentation The table below presents the fair value of the Company's derivative financial instruments as well as their classification on the balance sheet as of March 27, 2021: Balance Sheet Location March 27, 2021 September 26, 2020 Assets: Derivatives not designated as hedging instruments: Forward foreign currency contracts Prepaid expenses and other current assets $ — $ 1.1 Foreign currency option contracts Prepaid expenses and other current assets 1.1 10.1 $ 1.1 $ 11.2 Liabilities: Derivative instruments designated as a cash flow hedge: Interest rate swap contract Accrued expenses $ 11.0 $ 8.2 Interest rate swap contract Other long-term liabilities 13.9 23.0 Total $ 24.9 $ 31.2 Derivatives not designated as hedging instruments: Forward foreign currency contracts Accrued expenses $ 3.0 $ — The following table presents the unrealized gain (loss) recognized in AOCI related to the interest rate caps and interest rate swap for the following reporting periods: Three Months Ended Six Months Ended March 27, 2021 March 28, 2020 March 27, 2021 March 28, 2020 Amount of gain (loss) recognized in other comprehensive income, net of taxes: Interest rate swap $ 4.3 $ (25.2) $ 5.2 $ (20.8) Interest rate cap agreements — (0.1) (0.2) (0.4) Total $ 4.3 $ (25.3) $ 5.0 $ (21.2)

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Mar. 27, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Litigation and Related Matters On November 6, 2015, the Company filed a suit against Minerva Surgical, Inc. (“Minerva”) in the United States District Court for the District of Delaware, alleging that Minerva’s endometrial ablation device infringes U.S. Patent 6,872,183 (the '183 patent), U.S. Patent 8,998,898 and U.S. Patent 9,095,348 (the '348 patent). On January 25, 2016, the Company amended the complaint to include claims against Minerva for unfair competition, deceptive trade practices and tortious interference with business relationships. On February 5, 2016, the Company filed a second amended complaint to additionally allege that Minerva’s endometrial ablation device infringes U.S. Patent 9,247,989 (the '989 patent). On March 4, 2016, Minerva filed an answer and counterclaims against the Company, seeking declaratory judgment on the Company’s claims and asserting claims against the Company for unfair competition, deceptive trade practices, interference with contractual relationships, breach of contract and trade libel. On June 2, 2016, the Court denied the Company’s motion for a preliminary injunction on its patent claims and denied Minerva’s request for preliminary injunction related to the Company’s alleged false and deceptive statements regarding the Minerva product. On June 28, 2018, the Court granted the Company's summary judgment motions on infringement and no invalidity with respect to the ‘183 and ‘348 patents. The Court also granted the Company’s motion for summary judgment on assignor estoppel, which bars Minerva’s invalidity defenses or any reliance on collateral findings regarding invalidity from inter partes review proceedings. The Court also denied all of Minerva’s defenses, including its motions for summary judgment on invalidity, non-infringement, no willfulness, and no unfair competition. On July 27, 2018, after a two-week trial, a jury returned a verdict that: (1) awarded the Company $4.8 million in damages for Minerva’s infringement; (2) found that Minerva’s infringement was not willful; and (3) found for the Company regarding Minerva’s counterclaims. Damages continued to accrue as Minerva continues its infringing conduct. On May 2, 2019, the Court issued rulings that denied the parties' post-trial motions, including the Company's motion for a permanent injunction seeking to prohibit Minerva from selling infringing devices. Both parties appealed the Court's rulings regarding the post-trial motions. On March 4, 2016, Minerva filed two petitions at the USPTO for inter partes review of the '348 patent. On September 12, 2016, the PTAB declined both petitions to review patentability of the '348 patent. On April 11, 2016, Minerva filed a petition for inter partes review of the '183 patent. On October 6, 2016, the PTAB granted the petition and instituted a review of the '183 patent. On December 15, 2017, the PTAB issued a final written decision invalidating all claims of the ‘183 patent. On February 9, 2018 the Company appealed this decision to the United States Court of Appeals for the Federal Circuit ("Court of Appeals"). On April 19, 2019, the Court of Appeals affirmed the PTAB's final written decision regarding the '183 patent. On July 16, 2019, the Court of Appeals denied the Company’s petition for rehearing in the appeal regarding the '183 patent. On April 22, 2020, the Court of Appeals affirmed the district court’s summary judgment ruling in favor of the Company of no invalidity and infringement, and summary judgment that assignor estoppel bars Minerva from challenging the validity of the ‘348 patent. The Court of Appeals also denied the Company’s motion for a permanent injunction and ongoing royalties for infringement of the ‘183 patent. The Court of Appeals denied Minerva’s arguments for no damages or, alternatively, a new trial. On May 22, 2020 both parties petitioned for en banc review of the Court of Appeals decision. On July 22, 2020, the Court of Appeals denied both parties' petitions for en banc review. On August 28, 2020, the district court entered final judgment against Minerva but stayed execution pending resolution of Minerva’s petition for Supreme Court review. On September 30, 2020, Minerva filed a petition requesting Supreme Court review on the issue of assignor estoppel. On November 5, 2020, Hologic filed a cross-petition requesting Supreme Court review on the issue of assignor estoppel. On January 8, 2021, the Supreme Court granted Minerva’s petition to address the issue of assignor estoppel and denied Hologic's petition. Oral argument before the Supreme Court was held on April 21, 2021. On April 11, 2017, Minerva filed suit against the Company and Cytyc Surgical Products, LLC (“Cytyc”) in the United States District Court for the Northern District of California alleging that the Company’s and Cytyc’s NovaSure ADVANCED endometrial ablation device infringes Minerva’s U.S. patent 9,186,208. Minerva is seeking a preliminary and permanent injunction against the Company and Cytyc from selling this NovaSure device as well as enhanced damages and interest, including lost profits, price erosion and/or royalty. On January 5, 2018, the Court denied Minerva's motion for a preliminary injunction. On February 2, 2018, at the parties’ joint request, this action was transferred to the District of Delaware. On March 26, 2019, the Magistrate Judge issued a claims construction ruling regarding the disputed terms in the patent, which the District Court Judge adopted in all respects on October 21, 2019. The original trial date of July 20, 2020 was vacated. On October 21, 2020, the trial court scheduled a 10-day trial beginning on August 9, 2021. At this time, based on available information regarding this litigation, the Company is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses. As described in Note 7, the Company has agreed to indemnify CD&R for certain legal matters related to the Medical Aesthetics business that existed at the date of disposition. The Company currently has $10.0 million accrued for such matters as of March 27, 2021. While the Company believes the estimated amounts accrued are reasonable, certain matters are still ongoing and additional accruals could be recorded in the future. The Company is a party to various other legal proceedings and claims arising out of the ordinary course of its business. The Company believes that except for those matters described above there are no other proceedings or claims pending against it the ultimate resolution of which could have a material adverse effect on its financial condition or results of operations. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies . Legal costs are expensed as incurred.

Net Income (Loss) Per Share

Net Income (Loss) Per Share	6 Months Ended
	Mar. 27, 2021
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	Net Income Per Share A reconciliation of basic and diluted share amounts is as follows: Three Months Ended Six Months Ended March 27, March 28, March 27, March 28, Basic weighted average common shares outstanding 258,473 263,238 258,539 265,566 Weighted average common stock equivalents from assumed exercise of stock options and issuance of stock units 2,276 1,268 2,728 1,548 Diluted weighted average common shares outstanding 260,749 264,506 261,267 267,114 Weighted-average anti-dilutive shares related to: Outstanding stock options 552 1,677 446 1,483 Stock Units 2 10 1 6

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Mar. 28, 2020
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The following presents stock-based compensation expense in the Company’s Consolidated Statements of Income: Three Months Ended Six Months Ended March 27, March 28, March 27, March 28, Cost of revenues $ 2.3 $ 1.7 $ 4.5 $ 3.8 Research and development 2.3 2.3 4.8 4.6 Selling and marketing 2.7 2.8 5.4 5.6 General and administrative 9.7 6.5 20.9 17.4 Restructuring — 2.4 — 2.4 $ 17.0 $ 15.7 $ 35.6 $ 33.8 The Company granted options to purchase 0.6 million and 0.9 million shares of the Company's common stock during the six months ended March 27, 2021 and March 28, 2020, respectively, with weighted-average exercise prices of $68.64 and $45.82, respectively. There were 4.5 million options outstanding at March 27, 2021 with a weighted-average exercise price of $44.53. The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table: Three Months Ended Six Months Ended March 27, March 28, March 27, March 28, Risk-free interest rate 0.4 % 1.7 % 0.4 % 1.7 % Expected volatility 35.0 % 33.6 % 35.0 % 33.6 % Expected life (in years) 4.8 4.8 4.8 4.8 Dividend yield — — — — Weighted average fair value of options granted $ 21.17 $ 14.45 $ 20.08 $ 13.87 The Company granted 0.5 million and 0.8 million restricted stock units (RSUs) during the six months ended March 27, 2021 and March 28, 2020, respectively, with weighted-average grant date fair values of $68.51 and $45.76 per unit, respectively. In addition, the Company granted 0.1 million and 0.1 million performance stock units (PSUs) during the six months ended March 27, 2021 and March 28, 2020, respectively, to members of its senior management team, which have a weighted-average grant date fair value of $68.51 and $45.76 per unit, respectively. Each recipient of PSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of three years provided the Company’s defined Return on Invested Capital metrics are achieved. The Company also granted 0.1 million and 0.1 million of PSUs based on a one-year free cash flow measure (FCF) to its senior management team, which had a grant date fair value of $68.51 and $45.76 per unit during the six months ended March 27, 2021 and March 28, 2020, respectively. Each recipient of FCF PSUs is eligible to receive between zero and 200% of the target number of shares of the Company's common stock at the end of the one-year measurement period, but the FCF PSUs vest at the end of the three year service period. The PSUs and FCF PSUs cliff-vest three years from the date of grant, and the Company recognizes compensation expense ratably over the required service period based on its estimate of the number of shares that will vest upon achieving the measurement criteria. If there is a change in the estimate of the number of shares that are probable of vesting, the Company will cumulatively adjust compensation expense in the period that the change in estimate is made. The Company also granted 0.1 million and 0.1 million market-based awards (MSUs) to its senior management team during the three months ended March 27, 2021 and March 28, 2020, respectively. Each recipient of MSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of three years based upon achieving a certain total shareholder return relative to a defined peer group. The MSUs were valued at $82.31 and $43.90 per share using the Monte Carlo simulation model. These awards cliff-vest three years from the date of grant, and the Company recognizes compensation expense for the MSUs ratably over the service period. At March 27, 2021, there was 3.1 million in aggregate RSUs, PSUs, FCF PSUs and MSUs outstanding. At March 27, 2021, there was $23.0 million and $71.7 million of unrecognized compensation expense related to stock options and stock units (comprised of RSUs, PSUs, FCF PSUs and MSUs), respectively, to be recognized over a weighted-average period of 2.5 and 2.1 years, respectively.

Other Balance Sheet Information

Other Balance Sheet Information	6 Months Ended
	Mar. 27, 2021
Balance Sheet Related Disclosures [Abstract]
Other Balance Sheet Information	Other Balance Sheet Information March 27, September 26, Inventories Raw materials $ 154.2 $ 152.3 Work-in-process 56.4 46.5 Finished goods 245.6 196.3 $ 456.2 $ 395.1 Property, plant and equipment Equipment $ 491.5 $ 460.7 Equipment under customer usage agreements 471.6 456.8 Building and improvements 178.7 167.3 Leasehold improvements 47.0 44.3 Land 41.4 40.7 Furniture and fixtures 16.8 16.1 Right of use assets 8.4 — $ 1,255.4 $ 1,185.9 Less – accumulated depreciation and amortization (721.8) (694.4) $ 533.6 $ 491.5

Business Segments and Geographi

Business Segments and Geographic Information	6 Months Ended
	Mar. 27, 2021
Segment Reporting [Abstract]
Business Segments and Geographic Information	Business Segments and Geographic InformationDuring fiscal 2021, the Company had four reportable segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. During fiscal 2020, the Company had five reportable segments that included Medical Aesthetics. The Company completed the sale of its Medical Aesthetics business on December 30, 2019. The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges, such as intangible asset amortization expense, intangible asset and goodwill impairment charges, transaction and integration expenses for acquisitions, restructuring, consolidation and divestiture charges, litigation charges, and other one-time or unusual items. Identifiable assets for the reportable segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no inter-segment revenues during the three and six months ended March 27, 2021 and March 28, 2020. Segment information is as follows: Three Months Ended Six Months Ended March 27, March 28, March 27, March 28, Total revenues: Diagnostics $ 1,064.5 $ 319.2 $ 2,192.7 $ 630.7 Breast Health 336.3 307.8 669.1 638.9 GYN Surgical 114.2 105.4 238.2 224.5 Skeletal Health 22.6 23.7 47.4 47.2 Medical Aesthetics — — — 65.3 $ 1,537.6 $ 756.1 $ 3,147.4 $ 1,606.6 Income from operations: Diagnostics $ 700.6 $ 57.3 $ 1,485.0 $ 106.8 Breast Health 67.8 75.9 154.1 169.8 GYN Surgical 28.6 23.9 42.3 55.4 Skeletal Health (0.2) 1.7 0.8 2.6 Medical Aesthetics — (2.4) — (53.4) $ 796.8 $ 156.4 $ 1,682.2 $ 281.2 Depreciation and amortization: Diagnostics $ 59.1 $ 59.3 $ 115.4 $ 118.4 Breast Health 12.9 13.1 26.0 23.1 GYN Surgical 23.0 21.1 46.3 42.1 Skeletal Health 0.2 0.2 0.3 0.4 Medical Aesthetics — — — 4.1 $ 95.2 $ 93.7 $ 188.0 $ 188.1 Capital expenditures: Diagnostics $ 39.3 $ 17.1 $ 77.6 $ 35.3 Breast Health 2.7 8.1 5.6 14.5 GYN Surgical 3.2 5.3 6.5 10.6 Skeletal Health — 0.1 — 0.2 Medical Aesthetics — — — 1.4 Corporate 0.6 1.1 0.9 1.1 $ 45.8 $ 31.7 $ 90.6 $ 63.1 March 27, September 26, Identifiable assets: Diagnostics $ 2,584.1 $ 2,161.4 Breast Health 1,266.8 1,200.9 GYN Surgical 1,402.3 1,438.7 Skeletal Health 30.4 38.9 Corporate 2,760.4 2,355.9 $ 8,044.0 $ 7,195.8 The Company had no customers that represented greater than 10% of consolidated revenues during the three and six months ended March 27, 2021 and March 28, 2020. The Company operates in the following major geographic areas noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from France, the United Kingdom and Germany. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “Rest of world” designation includes Canada, Latin America and the Middle East. Revenues by geography as a percentage of total revenues were as follows: Three Months Ended Six Months Ended March 27, March 28, March 27, March 28, United States 69.2 % 76.0 % 70.0 % 75.1 % Europe 21.9 % 14.8 % 21.4 % 13.8 % Asia-Pacific 5.9 % 5.5 % 5.7 % 7.0 % Rest of World 3.0 % 3.7 % 2.9 % 4.1 % 100.0 % 100.0 % 100.0 % 100.0 %

Income Taxes

Income Taxes	6 Months Ended
	Mar. 27, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes In accordance with ASC 740, Income Taxes (ASC 740), each interim period is considered integral to the annual period, and tax expense is measured using an estimated annual effective tax rate. An entity is required to record income tax expense each quarter based on its annual effective tax rate estimated for the full fiscal year and use that rate to provide for income taxes on a current year-to-date basis, adjusted for discrete taxable events that occur during the interim period. The Company’s effective tax rate for the three and six months ended March 27, 2021 was a provision of 20.6% and 21.1%. respectively, compared to a provision of 20.3% and a net benefit of 122.1%, respectively, for the corresponding periods in the prior year. The effective tax rate for the three months ended March 27, 2021 was lower than the U.S. statutory tax rate primarily due to the impact of the U.S. deduction for foreign derived intangible income and the geographic mix of income earned by our international subsidiaries, which are taxed at rates lower than the U.S. statutory tax rate, partially offset by state income taxes. The effective tax rate for the six months ended March 27, 2021 was higher than the U.S. statutory tax rate primarily due to state income taxes, partially offset by the impact of the U.S. deduction for foreign derived intangible income and the geographic mix of income earned by our international subsidiaries, which are taxed at rates lower than the U.S. statutory tax rate. The effective tax rate for the three months ended March 28, 2020 differed from the U.S. statutory tax rate primarily due to taxation of foreign earnings at tax rates lower than the U.S. statutory tax rate including the impact of the U.S. tax imposed on global intangible low-taxed income and the U.S. deduction for foreign derived intangible income, partially offset by unbenefited foreign losses. The effective tax rate for the six months ended March 28, 2020 differed from the statutory tax rate primarily due to a $310.9 million discrete net tax benefit related to the loss on the sale of the Medical Aesthetics business. Non-Income Tax Matters The Company is subject to tax examinations for value-added, sales-based, payroll, and other non-income tax items. A number of these examinations are ongoing in various jurisdictions. The Company takes certain non-income tax positions in the jurisdictions in which it operates. In the normal course of business, the Company's positions and conclusions related to its non-income tax positions could be challenged, resulting in assessments by governmental authorities. Pursuant to ASC 450, the Company has recorded loss contingencies with respect to some of these positions. While the Company believes estimated losses previously recorded are reasonable, certain audits are still ongoing and additional charges could be recorded in the future.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	3 Months Ended
	Dec. 28, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	Intangible Assets Intangible assets consisted of the following: Description As of March 27, 2021 As of September 26, 2020 Gross Accumulated Gross Accumulated Acquired intangible assets: Developed technology $ 4,320.3 $ 3,033.9 $ 4,054.0 $ 2,907.2 Customer relationships 570.9 493.9 549.1 477.8 Trade names 248.6 186.2 245.5 181.2 Non-competition agreements 1.5 1.5 1.5 1.3 Business licenses 2.5 2.5 2.4 2.3 Total acquired intangible assets $ 5,143.8 $ 3,718.0 $ 4,852.5 $ 3,569.8 Internal-use software 55.2 46.8 51.8 43.2 Capitalized software embedded in products 25.9 12.5 26.8 10.6 Total intangible assets $ 5,224.9 $ 3,777.3 $ 4,931.1 $ 3,623.6 The estimated remaining amortization expense of the Company's acquired intangible assets as of March 27, 2021 for each of the five succeeding fiscal years is as follows: Remainder of Fiscal 2021 $ 153.3 Fiscal 2022 $ 303.9 Fiscal 2023 $ 207.4 Fiscal 2024 $ 195.3 Fiscal 2025 $ 181.9

Product Warranties

Product Warranties	6 Months Ended
	Mar. 27, 2021
Guarantees [Abstract]
Product Warranties	Product Warranties Product warranty activity was as follows: Balance at Provisions Acquired Divested Settlements/ Balance at Six Months Ended: March 27, 2021 $ 9.9 $ 4.8 $ — $ — $ (5.3) $ 9.4 March 28, 2020 $ 13.9 $ 5.5 $ 0.5 $ (6.1) $ (6.2) $ 7.6

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	6 Months Ended
	Mar. 27, 2021
Accumulated Other Comprehensive Income [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Income (Loss) The following tables summarize the changes in accumulated balances of other comprehensive loss for the periods presented: Three Months Ended March 27, 2021 Six Months Ended March 27, 2021 Foreign Currency Translation Pension Plans Hedged Interest Rate Caps Hedged Interest Rate Swaps Total Foreign Currency Translation Pension Plans Hedged Interest Rate Caps Hedged Interest Rate Swaps Total Beginning Balance $ (5.1) $ (1.8) $ (0.6) $ (23.2) $ (30.7) $ (22.9) $ (1.8) $ (0.9) $ (24.1) $ (49.7) Other comprehensive income (loss) before reclassifications (9.4) — 0.6 3.7 (5.1) 8.4 — 0.4 4.6 13.4 Amounts reclassified to statement of income — — — — — — — 0.5 — 0.5 Ending Balance $ (14.5) $ (1.8) $ — $ (19.5) $ (35.8) $ (14.5) $ (1.8) $ — $ (19.5) $ (35.8) Three Months Ended March 28, 2020 Six Months Ended March 28, 2020 Foreign Currency Translation Pension Plans Hedged Interest Rate Caps Hedged Interest Rate Swaps Total Foreign Currency Translation Pension Plans Hedged Interest Rate Caps Hedged Interest Rate Swaps Total Beginning Balance $ (33.1) $ (1.7) $ (1.4) $ 7.5 $ (28.7) $ (41.4) $ (1.7) $ (2.7) $ 3.5 $ (42.3) Other comprehensive income (loss) before reclassifications (5.4) — (0.1) (25.1) (30.6) 2.9 — (0.1) (21.1) (18.3) Amounts reclassified to statement of income — — 0.4 — 0.4 — — 1.7 — 1.7 Ending Balance $ (38.5) $ (1.7) $ (1.1) $ (17.6) $ (58.9) $ (38.5) $ (1.7) $ (1.1) $ (17.6) $ (58.9)

New Accounting Pronouncements

New Accounting Pronouncements	6 Months Ended
	Mar. 27, 2021
Accounting Policies [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements See Note 1 for Recently Adopted Accounting Pronouncements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board issued this Update as part of its initiative to reduce complexity in accounting standards (the Simplification Initiative). For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and is applicable to the Company in fiscal 2022. The Company is currently evaluating the impact of the adoption of ASU 2019-12 on its consolidated financial position and results of operations. In January 2020, the FASB issued ASU No. 2020-01, Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) . The Board issued this Update to clarify certain interactions between the guidance to account for certain equity securities under Topic 321, the guidance to account for investments under the equity method of accounting in Topic 323, and the guidance in Topic 815. This update could change how an entity accounts for an equity security under the measurement alternative or a forward contract or purchased option to purchase securities that, upon settlement of the forward contract or exercise of the purchased option, would be accounted for under the equity method of accounting or the fair value option in accordance with Topic 825, Financial Instruments. For entities that have adopted the amendments in Update 2020-01, the updated guidance is effective for annual periods beginning after December 15, 2020, and is applicable to the Company in fiscal 2022. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2020-01 on its consolidated financial position and results of operations. In January 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848) . The Board issued this Update as optional guidance for a limited period of time to ease the potential burden in accounting for or recognizing the effects of reference rate reform on financial reporting. This update will provide optional expedients and exceptions for applying GAAP to only contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. For entities that have adopted the amendments in Update 2020-04, the updated guidance is effective for all entities as of March 12, 2020 through December 31, 2022. The Company is currently evaluating the impact of the adoption of ASU 2020-04 on its consolidated financial position and results of operations. In January 2021, FASB issued ASU No. 2021-01, Reference Rate Reform (Topic 848) Scope.

New Accounting Pronouncements (

New Accounting Pronouncements (Policies)	6 Months Ended
	Mar. 27, 2021
Accounting Policies [Abstract]
New Accounting Pronouncements	In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board issued this Update as part of its initiative to reduce complexity in accounting standards (the Simplification Initiative). For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and is applicable to the Company in fiscal 2022. The Company is currently evaluating the impact of the adoption of ASU 2019-12 on its consolidated financial position and results of operations. In January 2020, the FASB issued ASU No. 2020-01, Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) . The Board issued this Update to clarify certain interactions between the guidance to account for certain equity securities under Topic 321, the guidance to account for investments under the equity method of accounting in Topic 323, and the guidance in Topic 815. This update could change how an entity accounts for an equity security under the measurement alternative or a forward contract or purchased option to purchase securities that, upon settlement of the forward contract or exercise of the purchased option, would be accounted for under the equity method of accounting or the fair value option in accordance with Topic 825, Financial Instruments. For entities that have adopted the amendments in Update 2020-01, the updated guidance is effective for annual periods beginning after December 15, 2020, and is applicable to the Company in fiscal 2022. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2020-01 on its consolidated financial position and results of operations. In January 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848) . The Board issued this Update as optional guidance for a limited period of time to ease the potential burden in accounting for or recognizing the effects of reference rate reform on financial reporting. This update will provide optional expedients and exceptions for applying GAAP to only contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. For entities that have adopted the amendments in Update 2020-04, the updated guidance is effective for all entities as of March 12, 2020 through December 31, 2022. The Company is currently evaluating the impact of the adoption of ASU 2020-04 on its consolidated financial position and results of operations. In January 2021, FASB issued ASU No. 2021-01, Reference Rate Reform (Topic 848) Scope.

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Mar. 27, 2021
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following tables provide revenue from contracts with customers by business and geographic region on a disaggregated basis: Three Months Ended March 27, 2021 Three Months Ended March 28, 2020 Business ( in millions ) United States International Total United States International Total Diagnostics: Cytology & Perinatal $ 76.8 $ 40.4 $ 117.2 $ 73.2 $ 40.2 $ 113.4 Molecular Diagnostics 616.4 318.9 935.3 149.8 40.8 190.6 Blood Screening 12.0 — 12.0 15.2 — 15.2 Total $ 705.2 $ 359.3 $ 1,064.5 $ 238.2 $ 81.0 $ 319.2 Breast Health: Breast Imaging $ 198.1 $ 71.8 $ 269.9 $ 186.0 $ 64.2 $ 250.2 Interventional Breast Solutions 54.9 11.5 66.4 48.4 9.2 57.6 Total $ 253.0 $ 83.3 $ 336.3 $ 234.4 $ 73.4 $ 307.8 GYN Surgical $ 91.7 $ 22.5 $ 114.2 $ 86.7 $ 18.7 $ 105.4 Skeletal Health $ 14.1 $ 8.5 $ 22.6 $ 15.6 $ 8.1 $ 23.7 $ 1,064.0 $ 473.6 $ 1,537.6 $ 574.9 $ 181.2 $ 756.1 Six Months Ended March 27, 2021 Six Months Ended March 28, 2020 Business (in millions) United States International Total United States International Total Diagnostics: Cytology & Perinatal $ 156.9 $ 85.1 $ 242.0 $ 150.7 $ 83.7 $ 234.4 Molecular Diagnostics 1,291.6 639.0 1,930.6 291.9 77.2 369.1 Blood Screening 20.1 — 20.1 27.2 — 27.2 Total $ 1,468.6 $ 724.1 $ 2,192.7 $ 469.8 $ 160.9 $ 630.7 Breast Health: Breast Imaging $ 401.1 $ 136.5 $ 537.6 $ 395.4 $ 129.6 $ 525.0 Interventional Breast Solutions 110.1 21.4 131.5 95.5 18.4 113.9 Total $ 511.2 $ 157.9 $ 669.1 $ 490.9 $ 148.0 $ 638.9 GYN Surgical $ 192.8 $ 45.4 $ 238.2 $ 185.5 $ 39.0 $ 224.5 Medical Aesthetics $ — $ — $ — $ 30.9 $ 34.4 $ 65.3 Skeletal Health $ 29.1 $ 18.3 $ 47.4 $ 30.5 $ 16.7 $ 47.2 $ 2,201.7 $ 945.7 $ 3,147.4 $ 1,207.6 $ 399.0 $ 1,606.6 Three Months Ended Six Months Ended Geographic Regions ( in millions ) March 27, 2021 March 28, 2020 March 27, 2021 March 28, 2020 United States $ 1,064.0 $ 574.9 $ 2,201.7 $ 1,207.6 Europe 336.8 111.8 675.0 221.2 Asia-Pacific 90.1 41.7 178.5 111.8 Rest of World 46.7 27.7 92.2 66.0 $ 1,537.6 $ 756.1 $ 3,147.4 $ 1,606.6 The following table provides revenue recognized by source: Three Months Ended Six Months Ended Revenue by type (in millions) March 27, 2021 March 28, 2020 March 27, 2021 March 28, 2020 Disposables $ 1,178.1 $ 457.0 $ 2,441.5 $ 923.4 Capital equipment, components and software 200.7 166.6 392.7 399.5 Service 141.8 127.2 278.9 272.2 Other 17.0 5.3 34.3 11.5 $ 1,537.6 $ 756.1 $ 3,147.4 $ 1,606.6

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Mar. 27, 2021
Fair Value Disclosures [Abstract]
Fair Value Assets and Liabilities Measured on Recurring Basis	Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following at March 27, 2021: Fair Value at Reporting Date Using Balance as of March 27, 2021 Quoted Prices in Significant Significant Assets: Foreign currency option contracts $ 1.1 $ — $ 1.1 $ — Total $ 1.1 $ — $ — $ — Liabilities: Contingent consideration $ 71.7 $ — $ — $ 71.7 Interest rate swap 24.9 — 24.9 — Forward foreign currency contracts 3.0 — 3.0 — Total $ 99.6 $ — $ 27.9 $ 71.7 Liabilities Measured and Recorded at Fair Value on a Recurring Basis Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of contingent consideration liabilities, during the three and six month periods ended March 27, 2021 and March 28, 2020 were as follows: Three Month Ended Six Months Ended March 27, 2021 March 28, 2020 March 27, 2021 March 28, 2020 Balance at beginning of period $ 86.4 $ 10.0 $ 81.8 $ 9.1 Contingent consideration recorded at acquisition — 0.9 — 0.9 Fair value adjustments (14.7) (0.5) (10.1) 0.4 Payments/Accruals — (9.6) — (9.6) Balance at end of period $ 71.7 $ 0.8 $ 71.7 $ 0.8

Business Combinations (Tables)

Business Combinations (Tables)	6 Months Ended
	Mar. 27, 2021
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The total purchase price was allocated to Biotheranostics' preliminary tangible and identifiable intangible assets and liabilities based on the estimated fair values as of February 22, 2021, as set forth below. Cash $ 9.6 Accounts receivable 2.9 Other assets 6.5 Accounts payable and accrued expenses (8.2) Other liabilities (8.1) Identifiable intangible assets: Developed technology 160.3 Trade names 2.1 Deferred income taxes, net (18.4) Goodwill 85.8 Purchase Price $ 232.5 The total purchase price was allocated to Diagenode's preliminary tangible and identifiable intangible assets and liabilities based on the estimated fair values as of March 1, 2021, as set forth below. Cash $ 5.6 Accounts receivable 9.1 Inventory 9.2 Other assets 13.8 Accounts payable and accrued expenses (9.2) Other liabilities (12.9) Identifiable intangible assets: Developed technology 69.8 Customer relationships 9.2 Deferred income taxes, net (19.3) Goodwill 78.1 Purchase Price $ 153.4 The total purchase price was allocated to Acessa's preliminary tangible and identifiable intangible assets and liabilities based on the estimated fair values as of August 23, 2020, as set forth below. Cash $ 1.2 Inventory 4.0 Other assets 4.4 Accounts payable and accrued expenses (4.7) Identifiable intangible assets: Developed technology 127.0 Trade names 1.2 Deferred income taxes, net (20.2) Goodwill 48.4 Purchase Price $ 161.3 Cash $ 2.6 Accounts receivable 7.1 Inventory 10.0 Property, plant and equipment 6.5 Other assets 4.3 Accounts payable and accrued expenses (24.5) Deferred revenue (1.8) Short and long-term debt (8.8) Other liabilities (3.8) Identifiable intangible assets: Developed technology 38.3 Customer relationships 4.0 Trade names 3.0 Deferred income taxes, net (1.9) Goodwill 34.3 Purchase Price $ 69.3

Trade Receivables and Allowan_2

Trade Receivables and Allowance for Credit Losses (Tables)	6 Months Ended
	Mar. 27, 2021
Receivables [Abstract]
Schedule of Accounts, Notes, Loans and Financing Receivable	The following is a rollforward of the allowance for credit losses as of March 27, 2021 compared to March 28, 2020:

Borrowings and Credit Arrange_2

Borrowings and Credit Arrangements (Tables)	6 Months Ended
	Mar. 27, 2021
Debt Disclosure [Abstract]
Company's Borrowings	The Company’s borrowings consisted of the following: March 27, September 26, Current debt obligations, net of debt discount and deferred issuance costs: Term Loan $ 74.9 $ 74.9 Revolver — 250.0 Total current debt obligations $ 74.9 $ 324.9 Long-term debt obligations, net of debt discount and issuance costs: Term Loan 1,343.6 1,379.9 2025 Senior Notes — 939.4 2028 Senior Notes 395.0 394.6 2029 Senior Notes 933.5 — Total long-term debt obligations $ 2,672.1 $ 2,713.9 Total debt obligations $ 2,747.0 $ 3,038.8
Schedule of Line of Credit Facilities	Interest expense, weighted average interest rates, and the interest rate at the end of period under the Credit Agreements were as follows: Three Months Ended Six Months Ended March 27, 2021 March 28, 2020 March 27, 2021 March 28, 2020 Interest expense $ 5.3 $ 13.0 $ 11.8 $ 26.6 Weighted average interest rate 1.12 % 2.75 % 1.17 % 2.93 % Interest rate at end of period 1.11 % 2.33 % 1.11 % 2.33 %
Schedule Of Interest Expense Under Convertible Notes	2029 Senior Notes As of March 27, 2021, the Company had 2029 Senior Notes outstanding in the aggregate principal balance of $950 million. The 2029 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain domestic subsidiaries. The 2029 Senior Notes mature on February 15, 2029 and bear interest at the rate of 3.250% per year, payable semi-annually on February 15 and August 15 of each year, commencing on February 15, 2021. The Company may redeem the 2029 Senior Notes at any time prior to September 28, 2023 at a price equal to 100% of the aggregate principal amount so redeemed, plus accrued and unpaid interest, if any, to the redemption date and a make-whole premium set forth in the indenture. The Company may also redeem up to 40% of the aggregate principal amount of the 2029 Senior Notes with the net cash proceeds of certain equity offerings at any time and from time to time before September 28, 2023, at a redemption price equal to 103.250% of the aggregate principal amount so redeemed, plus accrued and unpaid interest, if any, to the redemption date. The Company also has the option to redeem the 2029 Senior Notes on or after: September 28, 2023 through September 27, 2024 at 101.625% of par; September 28, 2024 through September 27, 2025 at 100.813% of par; and September 28, 2025 and thereafter at 100% of par. In addition, if the Company undergoes a change of control coupled with a decline in ratings, as provided in the indenture, the Company will be required to make an offer to purchase each holder’s 2029 Senior Notes at a price equal to 101% of their principal amount, plus accrued and unpaid interest, if any, to the repurchase date. The Company evaluated the 2029 Senior Notes for derivatives pursuant to ASC 815 and did not identify any embedded derivatives that require bifurcation. All features were deemed to be clearly and closely related to the host instrument. Interest expense for the 2029 Senior Notes, 2028 Senior Notes and 2025 Senior Notes was as follows: Three Months Ended Six Months Ended March 27, 2021 March 28, 2020 March 27, 2021 March 28, 2020 Interest Rate Interest Expense Interest Expense Interest Expense Interest Expense 2025 Senior Notes 4.375 % $ — $ 10.9 $ 2.3 $ 21.8 2028 Senior Notes 4.625 % 4.8 4.8 9.6 9.6 2029 Senior Notes 3.250 % 8.3 — 16.3 — Total $ 13.1 $ 15.7 $ 28.2 $ 31.4

Derivatives (Tables)

Derivatives (Tables)	6 Months Ended
	Mar. 27, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments, Gain (Loss)	Three Months Ended Six Months Ended March 27, 2021 March 28, 2020 March 27, 2021 March 28, 2020 Amount of realized gain (loss) recognized in income Forward foreign currency contracts $ 3.4 $ 0.1 $ 0.5 $ 0.1 Foreign currency option contracts (1.8) (0.5) (3.0) (0.7) $ 1.6 $ (0.4) $ (2.5) $ (0.6) Amount of unrealized gain (loss) recognized in income Forward foreign currency contracts $ 3.1 $ 2.6 $ (3.5) $ 1.1 Foreign currency option contracts 2.1 1.1 (5.9) (0.4) $ 5.2 $ 3.7 $ (9.4) $ 0.7 Amount of gain (loss) recognized in income Total $ 6.8 $ 3.3 $ (11.9) $ 0.1
Schedule of Derivative Assets at Fair Value	The table below presents the fair value of the Company's derivative financial instruments as well as their classification on the balance sheet as of March 27, 2021: Balance Sheet Location March 27, 2021 September 26, 2020 Assets: Derivatives not designated as hedging instruments: Forward foreign currency contracts Prepaid expenses and other current assets $ — $ 1.1 Foreign currency option contracts Prepaid expenses and other current assets 1.1 10.1 $ 1.1 $ 11.2 Liabilities: Derivative instruments designated as a cash flow hedge: Interest rate swap contract Accrued expenses $ 11.0 $ 8.2 Interest rate swap contract Other long-term liabilities 13.9 23.0 Total $ 24.9 $ 31.2 Derivatives not designated as hedging instruments: Forward foreign currency contracts Accrued expenses $ 3.0 $ —
Schedule of Unrealized Loss Recognized in AOCI	The following table presents the unrealized gain (loss) recognized in AOCI related to the interest rate caps and interest rate swap for the following reporting periods: Three Months Ended Six Months Ended March 27, 2021 March 28, 2020 March 27, 2021 March 28, 2020 Amount of gain (loss) recognized in other comprehensive income, net of taxes: Interest rate swap $ 4.3 $ (25.2) $ 5.2 $ (20.8) Interest rate cap agreements — (0.1) (0.2) (0.4) Total $ 4.3 $ (25.3) $ 5.0 $ (21.2)

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	6 Months Ended
	Mar. 27, 2021
Earnings Per Share [Abstract]
Reconciliation of Basic and Diluted Share Amounts	A reconciliation of basic and diluted share amounts is as follows: Three Months Ended Six Months Ended March 27, March 28, March 27, March 28, Basic weighted average common shares outstanding 258,473 263,238 258,539 265,566 Weighted average common stock equivalents from assumed exercise of stock options and issuance of stock units 2,276 1,268 2,728 1,548 Diluted weighted average common shares outstanding 260,749 264,506 261,267 267,114 Weighted-average anti-dilutive shares related to: Outstanding stock options 552 1,677 446 1,483 Stock Units 2 10 1 6

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Mar. 27, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation Expense in Consolidated Statements of Operations	The following presents stock-based compensation expense in the Company’s Consolidated Statements of Income: Three Months Ended Six Months Ended March 27, March 28, March 27, March 28, Cost of revenues $ 2.3 $ 1.7 $ 4.5 $ 3.8 Research and development 2.3 2.3 4.8 4.6 Selling and marketing 2.7 2.8 5.4 5.6 General and administrative 9.7 6.5 20.9 17.4 Restructuring — 2.4 — 2.4 $ 17.0 $ 15.7 $ 35.6 $ 33.8
Weighted-Average Assumptions Utilized to Value Stock Options	The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table: Three Months Ended Six Months Ended March 27, March 28, March 27, March 28, Risk-free interest rate 0.4 % 1.7 % 0.4 % 1.7 % Expected volatility 35.0 % 33.6 % 35.0 % 33.6 % Expected life (in years) 4.8 4.8 4.8 4.8 Dividend yield — — — — Weighted average fair value of options granted $ 21.17 $ 14.45 $ 20.08 $ 13.87

Other Balance Sheet Informati_2

Other Balance Sheet Information (Tables)	6 Months Ended
	Mar. 27, 2021
Balance Sheet Related Disclosures [Abstract]
Other Balance Sheet Information of Inventories	March 27, September 26, Inventories Raw materials $ 154.2 $ 152.3 Work-in-process 56.4 46.5 Finished goods 245.6 196.3 $ 456.2 $ 395.1
Other Balance Sheet Information of Property, Plant and Equipment	Property, plant and equipment Equipment $ 491.5 $ 460.7 Equipment under customer usage agreements 471.6 456.8 Building and improvements 178.7 167.3 Leasehold improvements 47.0 44.3 Land 41.4 40.7 Furniture and fixtures 16.8 16.1 Right of use assets 8.4 — $ 1,255.4 $ 1,185.9 Less – accumulated depreciation and amortization (721.8) (694.4) $ 533.6 $ 491.5

Business Segments and Geograp_2

Business Segments and Geographic Information (Tables)	6 Months Ended
	Mar. 27, 2021
Segment Reporting [Abstract]
Segment Information	egment information is as follows: Three Months Ended Six Months Ended March 27, March 28, March 27, March 28, Total revenues: Diagnostics $ 1,064.5 $ 319.2 $ 2,192.7 $ 630.7 Breast Health 336.3 307.8 669.1 638.9 GYN Surgical 114.2 105.4 238.2 224.5 Skeletal Health 22.6 23.7 47.4 47.2 Medical Aesthetics — — — 65.3 $ 1,537.6 $ 756.1 $ 3,147.4 $ 1,606.6 Income from operations: Diagnostics $ 700.6 $ 57.3 $ 1,485.0 $ 106.8 Breast Health 67.8 75.9 154.1 169.8 GYN Surgical 28.6 23.9 42.3 55.4 Skeletal Health (0.2) 1.7 0.8 2.6 Medical Aesthetics — (2.4) — (53.4) $ 796.8 $ 156.4 $ 1,682.2 $ 281.2 Depreciation and amortization: Diagnostics $ 59.1 $ 59.3 $ 115.4 $ 118.4 Breast Health 12.9 13.1 26.0 23.1 GYN Surgical 23.0 21.1 46.3 42.1 Skeletal Health 0.2 0.2 0.3 0.4 Medical Aesthetics — — — 4.1 $ 95.2 $ 93.7 $ 188.0 $ 188.1 Capital expenditures: Diagnostics $ 39.3 $ 17.1 $ 77.6 $ 35.3 Breast Health 2.7 8.1 5.6 14.5 GYN Surgical 3.2 5.3 6.5 10.6 Skeletal Health — 0.1 — 0.2 Medical Aesthetics — — — 1.4 Corporate 0.6 1.1 0.9 1.1 $ 45.8 $ 31.7 $ 90.6 $ 63.1 March 27, September 26, Identifiable assets: Diagnostics $ 2,584.1 $ 2,161.4 Breast Health 1,266.8 1,200.9 GYN Surgical 1,402.3 1,438.7 Skeletal Health 30.4 38.9 Corporate 2,760.4 2,355.9 $ 8,044.0 $ 7,195.8
Revenues by Geography	Revenues by geography as a percentage of total revenues were as follows: Three Months Ended Six Months Ended March 27, March 28, March 27, March 28, United States 69.2 % 76.0 % 70.0 % 75.1 % Europe 21.9 % 14.8 % 21.4 % 13.8 % Asia-Pacific 5.9 % 5.5 % 5.7 % 7.0 % Rest of World 3.0 % 3.7 % 2.9 % 4.1 % 100.0 % 100.0 % 100.0 % 100.0 %

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	6 Months Ended
	Mar. 27, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets consisted of the following: Description As of March 27, 2021 As of September 26, 2020 Gross Accumulated Gross Accumulated Acquired intangible assets: Developed technology $ 4,320.3 $ 3,033.9 $ 4,054.0 $ 2,907.2 Customer relationships 570.9 493.9 549.1 477.8 Trade names 248.6 186.2 245.5 181.2 Non-competition agreements 1.5 1.5 1.5 1.3 Business licenses 2.5 2.5 2.4 2.3 Total acquired intangible assets $ 5,143.8 $ 3,718.0 $ 4,852.5 $ 3,569.8 Internal-use software 55.2 46.8 51.8 43.2 Capitalized software embedded in products 25.9 12.5 26.8 10.6 Total intangible assets $ 5,224.9 $ 3,777.3 $ 4,931.1 $ 3,623.6
Schedule of Estimated Amortization Expense	The estimated remaining amortization expense of the Company's acquired intangible assets as of March 27, 2021 for each of the five succeeding fiscal years is as follows: Remainder of Fiscal 2021 $ 153.3 Fiscal 2022 $ 303.9 Fiscal 2023 $ 207.4 Fiscal 2024 $ 195.3 Fiscal 2025 $ 181.9

Product Warranties (Tables)

Product Warranties (Tables)	6 Months Ended
	Mar. 27, 2021
Guarantees [Abstract]
Product Warranty Activity	Product warranty activity was as follows: Balance at Provisions Acquired Divested Settlements/ Balance at Six Months Ended: March 27, 2021 $ 9.9 $ 4.8 $ — $ — $ (5.3) $ 9.4 March 28, 2020 $ 13.9 $ 5.5 $ 0.5 $ (6.1) $ (6.2) $ 7.6

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
	Mar. 27, 2021
Accumulated Other Comprehensive Income [Abstract]
Changes in Accumulated Other Comprehensive Income	The following tables summarize the changes in accumulated balances of other comprehensive loss for the periods presented: Three Months Ended March 27, 2021 Six Months Ended March 27, 2021 Foreign Currency Translation Pension Plans Hedged Interest Rate Caps Hedged Interest Rate Swaps Total Foreign Currency Translation Pension Plans Hedged Interest Rate Caps Hedged Interest Rate Swaps Total Beginning Balance $ (5.1) $ (1.8) $ (0.6) $ (23.2) $ (30.7) $ (22.9) $ (1.8) $ (0.9) $ (24.1) $ (49.7) Other comprehensive income (loss) before reclassifications (9.4) — 0.6 3.7 (5.1) 8.4 — 0.4 4.6 13.4 Amounts reclassified to statement of income — — — — — — — 0.5 — 0.5 Ending Balance $ (14.5) $ (1.8) $ — $ (19.5) $ (35.8) $ (14.5) $ (1.8) $ — $ (19.5) $ (35.8) Three Months Ended March 28, 2020 Six Months Ended March 28, 2020 Foreign Currency Translation Pension Plans Hedged Interest Rate Caps Hedged Interest Rate Swaps Total Foreign Currency Translation Pension Plans Hedged Interest Rate Caps Hedged Interest Rate Swaps Total Beginning Balance $ (33.1) $ (1.7) $ (1.4) $ 7.5 $ (28.7) $ (41.4) $ (1.7) $ (2.7) $ 3.5 $ (42.3) Other comprehensive income (loss) before reclassifications (5.4) — (0.1) (25.1) (30.6) 2.9 — (0.1) (21.1) (18.3) Amounts reclassified to statement of income — — 0.4 — 0.4 — — 1.7 — 1.7 Ending Balance $ (38.5) $ (1.7) $ (1.1) $ (17.6) $ (58.9) $ (38.5) $ (1.7) $ (1.1) $ (17.6) $ (58.9)

Basis of Presentation Details (

Basis of Presentation Details (Details) - USD ($) $ in Millions	Apr. 08, 2021	Nov. 21, 2019
Consideration transferred		$ 69.3
Mobidiag | Subsequent Event
Consideration transferred	$ 795

Revenue - Business Revenue (Det

Revenue - Business Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Disaggregation of Revenue [Line Items]
Revenues	$ 1,537,600,000	$ 756,100,000	$ 3,147,400,000	$ 1,606,600,000
Contract with Customer, Liability, Revenue Recognized	30,100,000	26,200,000	80,800,000	77,500,000
United States
Disaggregation of Revenue [Line Items]
Revenues	1,064,000,000	574,900,000	2,201,700,000	1,207,600,000
International
Disaggregation of Revenue [Line Items]
Revenues	473,600,000	181,200,000	945,700,000	399,000,000
Diagnostics
Disaggregation of Revenue [Line Items]
Revenues	1,064,500,000	319,200,000	2,192,700,000	630,700,000
Diagnostics | United States
Disaggregation of Revenue [Line Items]
Revenues	705,200,000	238,200,000	1,468,600,000	469,800,000
Diagnostics | International
Disaggregation of Revenue [Line Items]
Revenues	359,300,000	81,000,000	724,100,000	160,900,000
Diagnostics | Cytology & Perinatal
Disaggregation of Revenue [Line Items]
Revenues	117,200,000	113,400,000	242,000,000	234,400,000
Diagnostics | Cytology & Perinatal | United States
Disaggregation of Revenue [Line Items]
Revenues	76,800,000	73,200,000	156,900,000	150,700,000
Diagnostics | Cytology & Perinatal | International
Disaggregation of Revenue [Line Items]
Revenues	40,400,000	40,200,000	85,100,000	83,700,000
Diagnostics | Molecular Diagnostics
Disaggregation of Revenue [Line Items]
Revenues	935,300,000	190,600,000	1,930,600,000	369,100,000
Diagnostics | Molecular Diagnostics | United States
Disaggregation of Revenue [Line Items]
Revenues	616,400,000	149,800,000	1,291,600,000	291,900,000
Diagnostics | Molecular Diagnostics | International
Disaggregation of Revenue [Line Items]
Revenues	318,900,000	40,800,000	639,000,000	77,200,000
Diagnostics | Blood Screening
Disaggregation of Revenue [Line Items]
Revenues	12,000,000	15,200,000	20,100,000	27,200,000
Diagnostics | Blood Screening | United States
Disaggregation of Revenue [Line Items]
Revenues	12,000,000	15,200,000	20,100,000	27,200,000
Diagnostics | Blood Screening | International
Disaggregation of Revenue [Line Items]
Revenues	0	0	0	0
Breast Health
Disaggregation of Revenue [Line Items]
Revenues	336,300,000	307,800,000	669,100,000	638,900,000
Breast Health | United States
Disaggregation of Revenue [Line Items]
Revenues	253,000,000	234,400,000	511,200,000	490,900,000
Breast Health | International
Disaggregation of Revenue [Line Items]
Revenues	83,300,000	73,400,000	157,900,000	148,000,000
Breast Health | Breast Imaging
Disaggregation of Revenue [Line Items]
Revenues	269,900,000	250,200,000	537,600,000	525,000,000
Breast Health | Breast Imaging | United States
Disaggregation of Revenue [Line Items]
Revenues	198,100,000	186,000,000	401,100,000	395,400,000
Breast Health | Breast Imaging | International
Disaggregation of Revenue [Line Items]
Revenues	71,800,000	64,200,000	136,500,000	129,600,000
Breast Health | Interventional Breast Solutions
Disaggregation of Revenue [Line Items]
Revenues	66,400,000	57,600,000	131,500,000	113,900,000
Breast Health | Interventional Breast Solutions | United States
Disaggregation of Revenue [Line Items]
Revenues	54,900,000	48,400,000	110,100,000	95,500,000
Breast Health | Interventional Breast Solutions | International
Disaggregation of Revenue [Line Items]
Revenues	11,500,000	9,200,000	21,400,000	18,400,000
GYN Surgical
Disaggregation of Revenue [Line Items]
Revenues	114,200,000	105,400,000	238,200,000	224,500,000
GYN Surgical | United States
Disaggregation of Revenue [Line Items]
Revenues	91,700,000	86,700,000	192,800,000	185,500,000
GYN Surgical | International
Disaggregation of Revenue [Line Items]
Revenues	22,500,000	18,700,000	45,400,000	39,000,000
Medical Aesthetics
Disaggregation of Revenue [Line Items]
Revenues	0	0	0	65,300,000
Medical Aesthetics | United States
Disaggregation of Revenue [Line Items]
Revenues			0	30,900,000
Medical Aesthetics | International
Disaggregation of Revenue [Line Items]
Revenues			0	34,400,000
Skeletal Health
Disaggregation of Revenue [Line Items]
Revenues	22,600,000	23,700,000	47,400,000	47,200,000
Skeletal Health | United States
Disaggregation of Revenue [Line Items]
Revenues	14,100,000	15,600,000	29,100,000	30,500,000
Skeletal Health | International
Disaggregation of Revenue [Line Items]
Revenues	$ 8,500,000	$ 8,100,000	$ 18,300,000	$ 16,700,000

Revenue - Geographical Revenue

Revenue - Geographical Revenue (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Disaggregation of Revenue [Line Items]
Revenues	$ 1,537.6	$ 756.1	$ 3,147.4	$ 1,606.6
United States
Disaggregation of Revenue [Line Items]
Revenues	1,064	574.9	2,201.7	1,207.6
Europe
Disaggregation of Revenue [Line Items]
Revenues	336.8	111.8	675	221.2
Asia-Pacific
Disaggregation of Revenue [Line Items]
Revenues	90.1	41.7	178.5	111.8
Rest of World
Disaggregation of Revenue [Line Items]
Revenues	$ 46.7	$ 27.7	$ 92.2	$ 66

Revenue - Revenue by Type (Deta

Revenue - Revenue by Type (Details) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Disaggregation of Revenue [Line Items]
Revenues	$ 1,537,600,000	$ 756,100,000	$ 3,147,400,000	$ 1,606,600,000
Contract with Customer, Liability, Revenue Recognized	30,100,000	26,200,000	80,800,000	77,500,000
Disposables
Disaggregation of Revenue [Line Items]
Revenues	1,178,100,000	457,000,000	2,441,500,000	923,400,000
Capital equipment, components and software
Disaggregation of Revenue [Line Items]
Revenues	200,700,000	166,600,000	392,700,000	399,500,000
Service
Disaggregation of Revenue [Line Items]
Revenues	141,800,000	127,200,000	278,900,000	272,200,000
Other
Disaggregation of Revenue [Line Items]
Revenues	$ 17,000,000	$ 5,300,000	$ 34,300,000	$ 11,500,000

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Revenue from Contract with Customer [Abstract]
Revenue, Remaining Performance Obligation, Amount	$ 749,800,000		$ 749,800,000
Contract with Customer, Liability, Revenue Recognized	$ 30,100,000	$ 26,200,000	$ 80,800,000	$ 77,500,000

Revenue - Remaining Performance

Revenue - Remaining Performance Obligation (Details)	Mar. 27, 2021
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-03-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	22.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	6 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-03-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	33.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-03-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	23.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-03-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	14.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-03-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	8.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year

Leases - Additional Lease Infor

Leases - Additional Lease Information (Details)	3 Months Ended
	Mar. 27, 2021
Leases [Abstract]
Lease revenue as a percentage of total (percentage)	0.05

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) $ in Millions	Mar. 27, 2021USD ($)
Assets:
Assets measured at fair value on a recurring basis	$ 1.1
Liabilities:
Total	99.6
Foreign currency option contracts
Assets:
Assets measured at fair value on a recurring basis	1.1
Contingent consideration
Liabilities:
Contingent consideration	71.7
Interest rate swap
Assets:
Assets measured at fair value on a recurring basis	24.9
Forward foreign currency contracts | Liability
Assets:
Assets measured at fair value on a recurring basis	3
Quoted Prices in Active Market for Identical Assets (Level 1)
Assets:
Assets measured at fair value on a recurring basis	0
Liabilities:
Total	0
Quoted Prices in Active Market for Identical Assets (Level 1) | Foreign currency option contracts
Assets:
Assets measured at fair value on a recurring basis	0
Quoted Prices in Active Market for Identical Assets (Level 1) | Contingent consideration
Liabilities:
Contingent consideration	0
Quoted Prices in Active Market for Identical Assets (Level 1) | Interest rate swap
Assets:
Assets measured at fair value on a recurring basis	0
Quoted Prices in Active Market for Identical Assets (Level 1) | Forward foreign currency contracts | Liability
Assets:
Assets measured at fair value on a recurring basis	0
Significant Other Observable Inputs (Level 2)
Assets:
Assets measured at fair value on a recurring basis	0
Liabilities:
Total	27.9
Significant Other Observable Inputs (Level 2) | Foreign currency option contracts
Assets:
Assets measured at fair value on a recurring basis	1.1
Significant Other Observable Inputs (Level 2) | Contingent consideration
Liabilities:
Contingent consideration	0
Significant Other Observable Inputs (Level 2) | Interest rate swap
Assets:
Assets measured at fair value on a recurring basis	24.9
Significant Other Observable Inputs (Level 2) | Forward foreign currency contracts | Liability
Assets:
Assets measured at fair value on a recurring basis	3
Significant Unobservable Inputs (Level 3)
Assets:
Assets measured at fair value on a recurring basis	0
Liabilities:
Total	71.7
Significant Unobservable Inputs (Level 3) | Foreign currency option contracts
Assets:
Assets measured at fair value on a recurring basis	0
Significant Unobservable Inputs (Level 3) | Contingent consideration
Liabilities:
Contingent consideration	71.7
Significant Unobservable Inputs (Level 3) | Interest rate swap
Assets:
Assets measured at fair value on a recurring basis	0
Significant Unobservable Inputs (Level 3) | Forward foreign currency contracts | Liability
Assets:
Assets measured at fair value on a recurring basis	$ 0

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Sep. 26, 2020	Dec. 28, 2019	Mar. 27, 2021	Mar. 28, 2020
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Intangible asset and equipment impairment charges		$ 30.2	$ 0	$ 30.2
Borrowed principal			1,000
Credit Agreement
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Borrowed principal			1,400
2025 Senior Notes
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Fair value of debt instrument			421.7
2028 Senior Notes
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Fair value of debt instrument			$ 932.2
Medical Aesthetics
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Intangible asset and equipment impairment charges	$ 30.2

Fair Value Measurements - Roll

Fair Value Measurements - Roll Forward (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Fair Value Disclosures [Abstract]
Beginning balance	$ 86.4	$ 10	$ 81.8	$ 9.1
Contingent consideration recorded at acquisition	0	0.9	0	0.9
Fair value adjustments	(14.7)	(0.5)	(10.1)	0.4
Payments/Accruals	0	(9.6)	0	(9.6)
Ending balance	$ 71.7	$ 0.8	$ 71.7	$ 0.8

Business Combination - Narrativ

Business Combination - Narrative (Details) $ / shares in Units, shares in Millions, $ in Millions

Mar. 01, 2021USD ($)

Feb. 22, 2021USD ($)

Jan. 04, 2021USD ($)

Sep. 28, 2020USD ($)

Aug. 23, 2020USD ($)

Feb. 03, 2020USD ($)

Dec. 30, 2019USD ($)

Nov. 21, 2019USD ($)shares

Aug. 01, 2019USD ($)

Nov. 30, 2019USD ($)

Sep. 30, 2019$ / shares

Mar. 27, 2021USD ($)

Mar. 27, 2021USD ($)shares

Mar. 28, 2020

Sep. 26, 2020USD ($)

Nov. 20, 2019

Business Acquisition [Line Items]

Consideration transferred

$ 69.3

Intangible assets, net

$ 1,447.6

$ 1,447.6

$ 1,307.5

Goodwill

2,857.2

2,857.2

$ 2,657.9

Ownership percentage

78.00%

Equity interest in acquiree, remeasurement gain

$ 3.2

Consideration related to equity method investment

17.9

Consideration related to newly acquired shares

$ 12.6

Consideration, portion related to loan repayment

30.2

Consideration related to fair value of noncontrolling interest

8.6

Discount rate percentage

0.120

Developed Technology

Business Acquisition [Line Items]

Intangible assets useful life

10 years

Trade Names

Business Acquisition [Line Items]

Intangible assets useful life

10 years

Biotheranostics

Business Acquisition [Line Items]

Consideration transferred

$ 232.5

Intangible assets, fair value (percentage)

18.00%

Intangible assets useful life

10 years

Developed technology

$ 160.3

Trade names

2.1

Goodwill

$ 85.8

Diagenode

Business Acquisition [Line Items]

Consideration transferred

$ 153.4

Intangible assets useful life

10 years

Developed technology

$ 69.8

Customer relationships

9.2

Goodwill

$ 78.1

Diagenode | Customer Relationships

Business Acquisition [Line Items]

Intangible assets, fair value (percentage)

13.50%

Diagenode | Developed Technology

Business Acquisition [Line Items]

Intangible assets, fair value (percentage)

14.50%

Somatex Medical Technologies

Business Acquisition [Line Items]

Consideration transferred

$ 62.8

Developed technology

38

Customer relationships

1.2

Trade names

0.9

Net acquired tangible assets and liabilities

9.3

Goodwill

$ 32

NXC Imaging

Business Acquisition [Line Items]

Consideration transferred

$ 5.6

NXC Imaging | Customer Relationships

Business Acquisition [Line Items]

Intangible assets useful life

5 years

Acessa Health

Business Acquisition [Line Items]

Consideration transferred

$ 161.3

Intangible assets, fair value (percentage)

18.00%

Developed technology

$ 127

Trade names

1.2

Purchase price withheld

$ 81.8

Annual incremental revenue growth period

3 years

Change in contingent consideration

$ (14.7)

$ (10.1)

Goodwill

$ 48.4

Acessa Health | Contingent Holdback

Business Acquisition [Line Items]

Purchase price withheld

$ 3

Health Beacons

Business Acquisition [Line Items]

Consideration transferred

$ 19.7

Holdback

2.3

Intangible assets, net

10.7

Goodwill

6.2

Remainder of purchase price

$ 2.8

Alpha Imaging

Business Acquisition [Line Items]

Consideration transferred

$ 18

Purchase price withheld

0.9

Holdback

$ 1

Alpha Imaging | Customer Relationships

Business Acquisition [Line Items]

Intangible assets useful life

5 years

SuperSonic Imagine

Business Acquisition [Line Items]

Consideration transferred

12.6

$ 18.2

Developed technology

38.3

Customer relationships

4

Trade names

3

Goodwill

$ 34.3

Percentage of outstanding shares acquired

46.00%

50.00%

Cash tender offer price (per share) | $ / shares

$ 1.50

Shares acquired | shares

7.6

Equity interest in acquiree, percentage

46.00%

80.00%

80.00%

Additional outstanding shares purchased (in shares) | shares

1.1

Additional outstanding shares purchased, amount

$ 1.8

SuperSonic Imagine | Customer Relationships

Business Acquisition [Line Items]

Intangible assets useful life

9 years

SuperSonic Imagine | Developed Technology

Business Acquisition [Line Items]

Intangible assets useful life

9 years

SuperSonic Imagine | Trade Names

Business Acquisition [Line Items]

Intangible assets useful life

8 years 7 months 6 days

Business Combinations Business

Business Combinations Business Combinations - Purchase Price Allocation (Details) - USD ($) $ in Millions	Mar. 27, 2021	Mar. 01, 2021	Feb. 22, 2021	Sep. 26, 2020	Aug. 23, 2020	Nov. 21, 2019
Business Acquisition [Line Items]
Goodwill	$ 2,857.2			$ 2,657.9
Biotheranostics
Business Acquisition [Line Items]
Cash			$ 9.6
Accounts receivable			2.9
Other assets			6.5
Accounts payable and accrued expenses			(8.2)
Other liabilities			(8.1)
Developed technology			160.3
Trade names			2.1
Deferred income taxes, net			(18.4)
Goodwill			85.8
Purchase Price			$ 232.5
Diagenode
Business Acquisition [Line Items]
Cash		$ 5.6
Accounts receivable		9.1
Inventory		9.2
Other assets		13.8
Accounts payable and accrued expenses		(9.2)
Other liabilities		(12.9)
Developed technology		69.8
Customer relationships		9.2
Deferred income taxes, net		(19.3)
Goodwill		78.1
Purchase Price		$ 153.4
SuperSonic Imagine
Business Acquisition [Line Items]
Cash						$ 2.6
Accounts receivable						7.1
Inventory						10
Property, plant and equipment						6.5
Other assets						4.3
Accounts payable and accrued expenses						(24.5)
Deferred revenue						1.8
Short and long-term debt						(8.8)
Other liabilities						(3.8)
Developed technology						38.3
Customer relationships						4
Trade names						3
Deferred income taxes, net						(1.9)
Goodwill						34.3
Purchase Price						$ 69.3
Acessa Health
Business Acquisition [Line Items]
Cash					$ 1.2
Inventory					4
Other assets					4.4
Accounts payable and accrued expenses					(4.7)
Developed technology					127
Trade names					1.2
Deferred income taxes, net					(20.2)
Goodwill					48.4
Purchase Price					$ 161.3

Trade Receivables and Allowan_3

Trade Receivables and Allowance for Credit Losses (Details) - USD ($) $ in Millions	6 Months Ended
	Mar. 27, 2021	Mar. 28, 2020
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance at Beginning of Period	$ 31.6	$ 17.8
Credit Loss	12.5	5.5
Reclassified as Assets held for sale	0	(5.9)
Write- offs and Payments	(2.4)	(1.4)
Balance at End of Period	$ 41.7	$ 16

Disposition (Details)

Disposition (Details) - USD ($)	Nov. 20, 2019	Sep. 26, 2020	Dec. 28, 2019	Mar. 27, 2021	Mar. 28, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Intangible asset and equipment impairment charges			$ 30,200,000	$ 0	$ 30,200,000
Disposal Group, Including Discontinued Operation, Operating Income (Loss)			46,500,000
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Medical Aesthetics
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Consideration	$ 205,000,000
Proceeds from Divestiture of Businesses	$ 153,400,000
Indemnification liabily				$ 10,900,000
Disposal Group, Including Discontinued Operation, Segment that Includes Disposal Group		150.0 million
Cost of revenues
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Intangible asset and equipment impairment charges			25,800,000
Operating Expense
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Intangible asset and equipment impairment charges			$ 4,400,000

Borrowings and Credit Arrange_3

Borrowings and Credit Arrangements - Company's Borrowings (Detail) - USD ($) $ in Millions	Mar. 27, 2021	Sep. 26, 2020	Mar. 31, 2020
Debt Instrument [Line Items]
Current portion of long-term debt	$ 74.9	$ 324.9
Total long-term debt obligations	2,672.1	2,713.9
Total debt obligations	2,747	3,038.8
Term Loan
Debt Instrument [Line Items]
Current portion of long-term debt	74.9	74.9
Long term debt obligations. excluding convertible notes	1,343.6	1,379.9
Revolver
Debt Instrument [Line Items]
Current portion of long-term debt	0	250	$ 750
2025 Senior Notes
Debt Instrument [Line Items]
Long term debt obligations. excluding convertible notes	0	939.4
2028 Senior Notes
Debt Instrument [Line Items]
Long term debt obligations. excluding convertible notes	395	394.6
2029 Senior Notes
Debt Instrument [Line Items]
Long term debt obligations. excluding convertible notes	$ 933.5	$ 0

Borrowings and Credit Arrange_4

Borrowings and Credit Arrangements - Additional Information (Detail) - USD ($)	Oct. 15, 2020	Sep. 28, 2020	Mar. 27, 2021	Dec. 26, 2020	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020	Sep. 26, 2020	Mar. 31, 2020	Dec. 17, 2018
Debt Instrument [Line Items]
Long-term debt			$ 2,747,000,000			$ 2,747,000,000		$ 3,038,800,000
Debt extinguishment losses			0		$ 0	21,600,000	$ 0
Long-term Debt, Current Maturities			74,900,000			$ 74,900,000		324,900,000
Debt Instrument, Redemption Price, Percentage		40.00%
Amended Term Loan | Percentage Added to Eurodollar Rate
Debt Instrument [Line Items]
Basis spread on variable rate						1.00%
Revolver
Debt Instrument [Line Items]
Long-term Debt, Current Maturities			0			$ 0		250,000,000	$ 750,000,000
Debt Instrument, Unused Borrowing Capacity, Amount			1,500,000,000			$ 1,500,000,000
Revolving credit facility borrowings										$ 1,500,000,000
Senior Notes | 2025 Senior Notes
Debt Instrument [Line Items]
Debt extinguishment losses			$ (21,600,000)
Stated interest rate			4.375%			4.375%
Senior notes, face amount	$ 950,000,000		$ 950,000,000			$ 950,000,000
Interest Expense, Debt			5,800,000
Debt Issuance Costs, Net			7,900,000			7,900,000
Debt Instrument, Unamortized Discount			$ 6,400,000			$ 6,400,000
Premium payment	20,800,000
Extinguishment of Debt, Amount	$ 970,800,000
Senior Notes | 2028 Senior Notes
Debt Instrument [Line Items]
Stated interest rate			4.625%			4.625%
Senior Notes | 2029 Senior Notes
Debt Instrument [Line Items]
Stated interest rate		3.25%	3.25%			3.25%
Senior notes		$ 950,000,000	$ 950,000,000			$ 950,000,000
Debt Instrument, Offering Price, Percent Of Face Value		1
Debt Instrument, Redemption Price, Percentage		100.00%
Senior Notes | 2029 Senior Notes | Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage		103.25%
Senior Notes | 2029 Senior Notes | Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage		101.625%
Senior Notes | 2029 Senior Notes | Debt Instrument, Redemption, Period Three
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage		100.813%
Senior Notes | 2029 Senior Notes | Debt Instrument, Redemption, Period Four
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage		100.00%
Senior Notes | 2029 Senior Notes | Debt Instrument, Redemption, Period Five
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage		101.00%
2028 Senior Notes
Debt Instrument [Line Items]
Senior notes, face amount			400,000,000			400,000,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Repayments of Debt				$ 250,000,000
Term Loan
Debt Instrument [Line Items]
Long-term Debt, Current Maturities			74,900,000			74,900,000		$ 74,900,000
Debt Instrument, Unused Borrowing Capacity, Amount			$ 1,400,000,000			$ 1,400,000,000
Accounts Receivable Securitization
Debt Instrument [Line Items]
Repayments of Debt							$ 250,000,000

Borrowings and Credit Arrange_5

Borrowings and Credit Arrangements - Interest Expense Credit Agreement (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Line of Credit Facility [Line Items]
Interest expense	$ 13.1	$ 15.7	$ 28.2	$ 31.4
Credit Agreement
Line of Credit Facility [Line Items]
Interest expense	$ 5.3	$ 13	$ 11.8	$ 26.6
Weighted average interest rate	1.12%	2.75%	1.17%	2.93%
Interest rate at end of period	1.11%	2.33%	1.11%	2.33%

Borrowings and Credit Arrange_6

Borrowings and Credit Arrangements - Interest Expense Senior Notes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020	Sep. 28, 2020
Line of Credit Facility [Line Items]
Interest expense	$ 13.1	$ 15.7	$ 28.2	$ 31.4
Senior Notes | 2028 Senior Notes
Line of Credit Facility [Line Items]
Stated interest rate	4.625%		4.625%
Interest expense	$ 4.8	4.8	$ 9.6	9.6
Senior Notes | 2025 Senior Notes
Line of Credit Facility [Line Items]
Stated interest rate	4.375%		4.375%
Interest expense	$ 0	10.9	$ 2.3	21.8
Senior Notes | 2029 Senior Notes
Line of Credit Facility [Line Items]
Stated interest rate	3.25%		3.25%		3.25%
Interest expense	$ 8.3	$ 0	$ 16.3	$ 0

Derivatives - Additional Inform

Derivatives - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2019	Dec. 29, 2018	Mar. 27, 2021
Derivative [Line Items]
Interest Rate Cap Agreements Aggregate Premium Payable	$ 1.5	$ 3.7
Borrowed principal			$ 1,000
Notational Amount			415.8
Interest rate swap
Derivative [Line Items]
Derivative notional amount			$ 1,000
Variable interest rate			1.23%
Interest rate swap at fair value			$ 24.9
Foreign Exchange Option
Derivative [Line Items]
Derivative notional amount			$ 133.5

Derivatives - Schedule Of Chang

Derivatives - Schedule Of Change in Fair Value Of Derivative Contracts (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Total	$ 6.8	$ 3.3	$ (11.9)	$ 0.1
Derivatives not designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Amount of realized gain (loss) recognized in income	1.6	(0.4)	(2.5)	(0.6)
Amount of unrealized gain (loss) recognized in income	5.2	3.7	(9.4)	0.7
Forward foreign currency contracts | Derivatives not designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Amount of realized gain (loss) recognized in income	3.4	0.1	0.5	0.1
Amount of unrealized gain (loss) recognized in income	3.1	2.6	(3.5)	1.1
Foreign currency option contracts | Derivatives not designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Amount of realized gain (loss) recognized in income	(1.8)	(0.5)	(3)	(0.7)
Amount of unrealized gain (loss) recognized in income	$ 2.1	$ 1.1	$ (5.9)	$ (0.4)

Derivatives - Fair Value of Der

Derivatives - Fair Value of Derivative Financial Instruments (Details) - USD ($) $ in Millions	Mar. 27, 2021	Sep. 26, 2020
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative liability	$ 24.9	$ 31.2
Interest rate swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swap at fair value	24.9
Derivatives not designated as hedging instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative asset	1.1	11.2
Derivatives not designated as hedging instruments | Forward foreign currency contracts | Prepaid expenses and other current assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swap at fair value	0	1.1
Derivatives not designated as hedging instruments | Forward foreign currency contracts | Accrued expenses
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swap at fair value	3	0
Derivatives not designated as hedging instruments | Foreign currency option contracts | Prepaid expenses and other current assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative asset	1.1	10.1
Derivatives not designated as hedging instruments | Interest rate swap | Accrued expenses
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swap at fair value	11	8.2
Derivatives not designated as hedging instruments | Interest rate swap | Other long-term liabilities
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swap at fair value	$ 13.9	$ 23

Derivatives - Gain (Loss) on Fa

Derivatives - Gain (Loss) on Fair Value Hedges Recognized in AOCI (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in other comprehensive income, net of taxes:	$ (4.3)	$ 25.3	$ (5)	$ 21.2
Changes in value of hedged interest rate swaps and interest rate caps, net of tax of $1.4 and $1.2 for the three and six months ended March 27, 2021 and $(8.1) and $(6.4) for the three and six months ended March 28, 2020.	4.3	(25.2)	5	(21.2)
Interest Rate Swap
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in other comprehensive income, net of taxes:	(4.3)	(25.2)	(5.2)	20.8
Interest rate caps - derivative
Derivative Instruments, Gain (Loss) [Line Items]
Changes in value of hedged interest rate swaps and interest rate caps, net of tax of $1.4 and $1.2 for the three and six months ended March 27, 2021 and $(8.1) and $(6.4) for the three and six months ended March 28, 2020.	$ 0	$ (0.1)	$ (0.2)	$ (0.4)

Commitments and Contingencies (

Commitments and Contingencies (Detail)	Mar. 04, 2016petition	Mar. 27, 2021USD ($)	Jul. 27, 2018USD ($)
Minerva
Loss Contingencies [Line Items]
Assessed damages			$ 4,800,000
Petitions filed | petition	2
Medical Aesthetics
Loss Contingencies [Line Items]
Legal Accrual		$ 10,000,000

Net Income (Loss) Per Share - R

Net Income (Loss) Per Share - Reconciliation of Basic and Diluted Share Amounts (Detail) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Earnings Per Share [Line Items]
Basic weighted average common shares outstanding	258,473	263,238	258,539	265,566
Weighted average common stock equivalents from assumed exercise of stock options and issuance of stock units	2,276	1,268	2,728	1,548
Diluted weighted average common shares outstanding	260,749	264,506	261,267	267,114
Outstanding Stock Options and stock units
Weighted-average anti-dilutive shares related to:
Weighted-average anti-dilutive shares (in shares)	552	1,677	446	1,483
Restricted stock units
Weighted-average anti-dilutive shares related to:
Weighted-average anti-dilutive shares (in shares)	2	10	1	6

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 17	$ 15.7	$ 35.6	$ 33.8
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2.3	1.7	4.5	3.8
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2.3	2.3	4.8	4.6
Selling and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2.7	2.8	5.4	5.6
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	9.7	6.5	20.9	17.4
Restructuring Charges [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 0	$ 2.4	$ 0	$ 2.4

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	6 Months Ended
	Mar. 27, 2021	Mar. 28, 2020
Stock option plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted	0.6	0.9
Weighted-average exercise prices	$ 68.64	$ 45.82
Share-based compensation, stock option outstanding	4.5
Weighted-average exercise price of options outstanding	$ 44.53
Unrecognized compensation expense	$ 23
Weighted-average period for recognition of unrecognized stock-based compensation, years	2 years 6 months
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted	0.5	0.8
Restricted stock units (RSUs), weighted average grant date fair values	$ 68.51	$ 45.76
Unrecognized compensation expense	$ 71.7
Weighted-average period for recognition of unrecognized stock-based compensation, years	2 years 1 month 6 days
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted	0.1	0.1
Restricted stock units (RSUs), weighted average grant date fair values	$ 68.51	$ 45.76
Market Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted	0.1	0.1
Restricted stock units (RSUs), weighted average grant date fair values	$ 82.31	$ 43.90
Minimum eligible percentage to receive target number of shares of company's common stock	0.00%
Maximum eligible percentage to receive target number of shares of company's common stock	200.00%
Performance stock units vesting period	3 years
PSU Free Cash Flow [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted	0.1	0.1
Restricted stock units (RSUs), weighted average grant date fair values	$ 68.51	$ 45.76
Maximum eligible percentage to receive target number of shares of company's common stock	200.00%
RSU, PSU, MSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	3.1

Stock-Based Compensation - Weig

Stock-Based Compensation - Weighted-Average Assumptions Utilized to Value Stock Options (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Share-based Payment Arrangement [Abstract]
Risk-free interest rate	0.40%	1.70%	0.40%	1.70%
Expected volatility	35.00%	33.60%	35.00%	33.60%
Expected life (in years)	4 years 9 months 18 days	4 years 9 months 18 days	4 years 9 months 18 days	4 years 9 months 18 days
Dividend yield	$ 0	$ 0	$ 0	$ 0
Weighted average fair value of options granted	$ 21.17	$ 14.45	$ 20.08	$ 13.87

Other Balance Sheet Informati_3

Other Balance Sheet Information - Inventories (Detail) - USD ($) $ in Millions	Mar. 27, 2021	Sep. 26, 2020
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 154.2	$ 152.3
Work-in-process	56.4	46.5
Finished goods	245.6	196.3
Inventories	$ 456.2	$ 395.1

Other Balance Sheet Informati_4

Other Balance Sheet Information - Property, Plant and Equipment (Detail) - USD ($) $ in Millions	Mar. 27, 2021	Sep. 26, 2020
Balance Sheet Related Disclosures [Abstract]
Equipment	$ 491.5	$ 460.7
Equipment under customer usage agreements	471.6	456.8
Building and improvements	178.7	167.3
Leasehold improvements	47	44.3
Land	41.4	40.7
Furniture and fixtures	16.8	16.1
Finance Lease, Right-of-Use Asset, after Accumulated Amortization	8.4	0
Property, plant and equipment, gross	1,255.4	1,185.9
Less – accumulated depreciation and amortization	(721.8)	(694.4)
Property, plant and equipment, net	$ 533.6	$ 491.5

Business Segments and Geograp_3

Business Segments and Geographic Information - Additional Information (Detail)	3 Months Ended			6 Months Ended		9 Months Ended
	Mar. 27, 2021USD ($)	Sep. 26, 2020Segment	Mar. 28, 2020USD ($)	Mar. 27, 2021USD ($)	Mar. 28, 2020USD ($)	Jun. 27, 2020Segment
Segment Reporting Disclosure [Line Items]
Number of reportable segments | Segment		5				5
Revenues	$ 1,537,600,000		$ 756,100,000	$ 3,147,400,000	$ 1,606,600,000
Intersegment
Segment Reporting Disclosure [Line Items]
Revenues	$ 0		$ 0	$ 0	$ 0

Business Segments and Geograp_4

Business Segments and Geographic Information - Segment Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020	Sep. 26, 2020
Segment Reporting Information [Line Items]
Total revenues	$ 1,537.6	$ 756.1	$ 3,147.4	$ 1,606.6
Income (loss) from operations	796.8	156.4	1,682.2	281.2
Depreciation and amortization	95.2	93.7	188	188.1
Capital expenditures	45.8	31.7	90.6	63.1
Identifiable assets	8,044		8,044		$ 7,195.8
Diagnostics
Segment Reporting Information [Line Items]
Total revenues	1,064.5	319.2	2,192.7	630.7
Income (loss) from operations	700.6	57.3	1,485	106.8
Depreciation and amortization	59.1	59.3	115.4	118.4
Capital expenditures	39.3	17.1	77.6	35.3
Identifiable assets	2,584.1		2,584.1		2,161.4
Breast Health
Segment Reporting Information [Line Items]
Total revenues	336.3	307.8	669.1	638.9
Income (loss) from operations	67.8	75.9	154.1	169.8
Depreciation and amortization	12.9	13.1	26	23.1
Capital expenditures	2.7	8.1	5.6	14.5
Identifiable assets	1,266.8		1,266.8		1,200.9
GYN Surgical
Segment Reporting Information [Line Items]
Total revenues	114.2	105.4	238.2	224.5
Income (loss) from operations	28.6	23.9	42.3	55.4
Depreciation and amortization	23	21.1	46.3	42.1
Capital expenditures	3.2	5.3	6.5	10.6
Identifiable assets	1,402.3		1,402.3		1,438.7
Skeletal Health
Segment Reporting Information [Line Items]
Total revenues	22.6	23.7	47.4	47.2
Income (loss) from operations	(0.2)	1.7	0.8	2.6
Depreciation and amortization	0.2	0.2	0.3	0.4
Capital expenditures	0	0.1	0	0.2
Identifiable assets	30.4		30.4		38.9
Medical Aesthetics
Segment Reporting Information [Line Items]
Total revenues	0	0	0	65.3
Income (loss) from operations	0	(2.4)	0	(53.4)
Depreciation and amortization	0	0	0	4.1
Capital expenditures	0	0	0	1.4
Corporate
Segment Reporting Information [Line Items]
Capital expenditures	0.6	$ 1.1	0.9	$ 1.1
Identifiable assets	$ 2,760.4		$ 2,760.4		$ 2,355.9

Business Segments and Geograp_5

Business Segments and Geographic Information - Revenues by Geography (Detail)	3 Months Ended		6 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Schedule Of Geographical Segments [Line Items]
Revenues	100.00%	100.00%	100.00%	100.00%
United States
Schedule Of Geographical Segments [Line Items]
Revenues	69.20%	76.00%	70.00%	75.10%
Europe
Schedule Of Geographical Segments [Line Items]
Revenues	21.90%	14.80%	21.40%	13.80%
Asia-Pacific
Schedule Of Geographical Segments [Line Items]
Revenues	5.90%	5.50%	5.70%	7.00%
Rest of World
Schedule Of Geographical Segments [Line Items]
Revenues	3.00%	3.70%	2.90%	4.10%

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Segment Reporting Information [Line Items]
Company's effective tax rate	20.60%	20.30%	21.10%	12210.00%
Medical Aesthetics
Segment Reporting Information [Line Items]
Unrecognized Tax Benefits		$ 310,900,000		$ 310,900,000

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Schedule of Intangible Assets (Detail) - USD ($) $ in Millions	Mar. 27, 2021	Sep. 26, 2020
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 5,224.9	$ 4,931.1
Accumulated Amortization	3,777.3	3,623.6
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	4,320.3	4,054
Accumulated Amortization	3,033.9	2,907.2
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	570.9	549.1
Accumulated Amortization	493.9	477.8
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	248.6	245.5
Accumulated Amortization	186.2	181.2
Non-competition agreements
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	1.5	1.5
Accumulated Amortization	1.5	1.3
Business licenses
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	2.5	2.4
Accumulated Amortization	2.5	2.3
Total acquired intangible assets
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	5,143.8	4,852.5
Accumulated Amortization	3,718	3,569.8
Internal-use software
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	55.2	51.8
Accumulated Amortization	46.8	43.2
Capitalized software embedded in products
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	25.9	26.8
Accumulated Amortization	$ 12.5	$ 10.6

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Schedule of Estimated Amortization Expense (Detail) $ in Millions	Mar. 27, 2021USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of Fiscal 2021	$ 153.3
Fiscal 2022	303.9
Fiscal 2023	207.4
Fiscal 2024	195.3
Fiscal 2025	$ 181.9

Product Warranties - Product Wa

Product Warranties - Product Warranty Activity (Detail) - USD ($) $ in Millions	6 Months Ended
	Mar. 27, 2021	Mar. 28, 2020
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]
Balance at Beginning of Period	$ 9.9	$ 13.9
Provisions	4.8	5.5
Standard and Extended Product Warranty Accrual, Additions from Business Acquisition	0	0.5
Standard Product Warranty Accrual, Period Increase (Decrease)	0	(6.1)
Settlements/ Adjustments	(5.3)	(6.2)
Balance at End of Period	$ 9.4	$ 7.6

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance			$ 2,705.2	$ 2,115.7
Changes in foreign currency translation adjustment	$ (9.4)	$ (5.4)	8.4	2.9
Other comprehensive income (loss) before reclassifications	4.3	(25.2)	5	(21.2)
Ending balance	3,794.4		3,794.4
Foreign Currency Translation
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(5.1)	(33.1)	(22.9)	(41.4)
Changes in foreign currency translation adjustment	(9.4)	(5.4)	8.4	2.9
Amounts reclassified to statement of income	0	0	0	0
Ending balance	(14.5)	(38.5)	(14.5)	(38.5)
Pension Plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(1.8)	(1.7)	(1.8)	(1.7)
Other comprehensive income (loss) before reclassifications	0	0	0	0
Amounts reclassified to statement of income	0	0	0	0
Ending balance	(1.8)	(1.7)	(1.8)	(1.7)
Total
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(30.7)	(28.7)	(49.7)	(42.3)
Other comprehensive income (loss) before reclassifications				(18.3)
Amounts reclassified to statement of income	0	0.4	(0.5)	1.7
Other comprehensive income (loss) before reclassifications	(5.1)	(30.6)	13.4
Ending balance	(35.8)	(58.9)	(35.8)	(58.9)
Interest rate caps - derivative | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(0.6)	(1.4)	(0.9)	(2.7)
Other comprehensive income (loss) before reclassifications	0.6	(0.1)	0.4	(0.1)
Amounts reclassified to statement of income	0	(0.4)	(0.5)	(1.7)
Ending balance	0	(1.1)	0	(1.1)
Interest Rate Swap | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(23.2)	7.5	(24.1)	3.5
Other comprehensive income (loss) before reclassifications	3.7	(25.1)	4.6	(21.1)
Amounts reclassified to statement of income	0	0	0	0
Ending balance	$ (19.5)	$ (17.6)	$ (19.5)	$ (17.6)

Share Repurchase Share repurcha

Share Repurchase Share repurchase (Details) - USD ($)	3 Months Ended
	Mar. 27, 2021	Dec. 26, 2020	Dec. 11, 2019
December 11, 2019
share repurchase plan [Line Items]
Stock Repurchase Program, Authorized Amount			$ 500,000,000
December 11, 2020
share repurchase plan [Line Items]
Stock Repurchase Program, Authorized Amount			$ 1,000,000,000
December 11, 2019
share repurchase plan [Line Items]
Stock Repurchased During Period, Shares		1,500,000
Repurchase of equity		$ 101,300,000
December 11, 2020
share repurchase plan [Line Items]
Stock Repurchased During Period, Shares	1,600,000
Repurchase of equity	$ 120,100,000
Stock Repurchase Program, Remaining Authorized Repurchase Amount	$ 880,000,000